Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1)

Current Medicinal Chemistry

Volumn 18, Issue 3, 2011, Pages 439-481

  He, S M ^a   Li, R ^b   Kanwar, J R ^c   Zhou, S F ^d  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Homology model; Inhibitor; MRP1; Mutation; Structure activity relationship; Substrate

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CONJUGATED ESTROGEN; DOXORUBICIN; EPIPODOPHYLLOTOXIN; GLYCOPROTEIN P; LEUKOTRIENE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; VINCRISTINE; XENOBIOTIC AGENT;

ARTICLE; BRAIN; ENZYME SPECIFICITY; GENE SILENCING; HUMAN; INTESTINE; KIDNEY; LIVER; NONHUMAN; PELLET EXTRUSION; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TUMOR RESISTANCE;

EID: 79251514280     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794839197     Document Type: Article

References (459)

1. Rees, D.C.; Johnson, E.; Lewinson, O. ABC transporters: The power to change. Nat. Rev. Mol. Cell. Biol. 2009, 10, 218-227.
2. Jones, P.M.; O'Mara, M.L.; George, A.M. ABC transporters: A riddle wrapped in a mystery inside an enigma. Trends Biochem. Sci. 2009, 34, 520-531.
3. Jones, P.M.; George, A.M. The ABC transporter structure and mechanism: Perspectives on recent research. Cell. Mol. Life Sci. 2004, 61, 682-699.
4. Higgins, C.F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007, 446, 749-757.
5. van de Ven, R.; Oerlemans, R.; van der Heijden, J.W.; Scheffer, G.L.; de Gruijl, T.D.; Jansen, G.; Scheper, R.J. ABC drug transporters and immunity: Novel therapeutic targets in autoimmunity and cancer. J. Leukoc. Biol. 2009, 86, 1075-1087.
6. Borst, P.; Elferink, R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002, 71, 537-592.
7. Colabufo, N.A.; Berardi, F.; Contino, M.; Niso, M.; Perrone, R. ABC pumps and their role in active drug transport. Curr. Top. Med. Chem. 2009, 9, 119-129.
8. Seeger, M.A.; van Veen, H.W. Molecular basis of multidrug transport by ABC transporters. Biochim. Biophys. Acta. 2009, 1794, 725-737.
9. Szakacs, G.; Varadi, A.; Ozvegy-Laczka, C.; Sarkadi, B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today 2008, 13, 379-393.
10. Huls, M.; Russel, F.G.; Masereeuw, R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J. Pharmacol. Exp. Ther. 2009, 328, 3-9.
11. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: The multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
12. Eckford, P.D.; Sharom, F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 2009, 109, 2989-3011.
13. Fletcher, J.I.; Haber, M.; Henderson, M.J.; Norris, M.D. ABC transporters in cancer: More than just drug efflux pumps. Nat. Rev. Cancer 2010, 10, 147-156.
14. Gillet, J.P.; Efferth, T.; Remacle, J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 2007, 1775, 237-262.
15. Klein, I.; Sarkadi, B.; Varadi, A. An inventory of the human ABC proteins. Biochim. Biophys. Acta 1999, 1461, 237-262.
16. Locher, K.P. Structure and mechanism of ABC transporters. Curr. Opin. Struct. Biol. 2004, 14, 426-431.
17. Oldham, M.L.; Davidson, A.L.; Chen, J. Structural insights into ABC transporter mechanism. Curr. Opin. Struct. Biol. 2008, 18, 726-733.
18. Higgins, C.F.; Linton, K.J. Structural biology. The xyz of ABC transporters. Science 2001, 293, 1782-1784.
19. Sharom, F.J. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 2008, 9, 105-127.
20. Jemnitz, K.; Heredi-Szabo, K.; Janossy, J.; Ioja, E.; Vereczkey, L.; Krajcsi, P. ABCC2/Abcc2: A multispecific transporter with dominant excretory functions. Drug Metab. Rev. 2010, 42, 402-436.
21. Toh, S.; Wada, M.; Uchiumi, T.; Inokuchi, A.; Makino, Y.; Horie, Y.; Adachi, Y.; Sakisaka, S.; Kuwano, M. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 1999, 64, 739-746.
22. Nezasa, K.; Tian, X.; Zamek-Gliszczynski, M.J.; Patel, N.J.; Raub, T.J.; Brouwer, K.L. Altered hepatobiliary disposition of 5 (and 6)- carboxy-2',7'-dichlorofluorescein in Abcg2 (Bcrp1) and Abcc2 (Mrp2) knockout mice. Drug Metab. Dispos. 2006, 34, 718-723.
23. Zelcer, N.; van de Wetering, K.; de Waart, R.; Scheffer, G.L.; Marschall, H.U.; Wielinga, P.R.; Kuil, A.; Kunne, C.; Smith, A.; van der Valk, M.; Wijnholds, J.; Elferink, R.O.; Borst, P. Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. J. Hepatol. 2006, 44, 768-775.
24. Chen, Z.S.; Lee, K.; Kruh, G.D. Transport of cyclic nucleotides and estradiol 17-β-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J. Biol. Chem. 2001, 276, 33747-33754.
25. Wijnholds, J.; Mol, C.A.; van Deemter, L.; de Haas, M.; Scheffer, G.L.; Baas, F.; Beijnen, J.H.; Scheper, R.J.; Hatse, S.; De Clercq, E.; Balzarini, J.; Borst, P. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 7476-7481.
26. McAleer, M.A.; Breen, M.A.; White, N.L.; Matthews, N. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J. Biol. Chem. 1999, 274, 23541-23548.
27. Zeng, H.; Liu, G.; Rea, P.A.; Kruh, G.D. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. 2000, 60, 4779-4784.
28. Jedlitschky, G.; Leier, I.; Buchholz, U.; Barnouin, K.; Kurz, G.; Keppler, D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996, 56, 988-994. (Pubitemid 26065391)
29. Loe, D.W.; Almquist, K.C.; Cole, S.P.; Deeley, R.G. ATPdependent 17 beta-estradiol 17-(beta-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J. Biol. Chem. 1996, 271, 9683-9689.
30. 4 (MRP4). J. Pharmacol. Exp. Ther. 2008, 324, 86-94.
31. Belinsky, M.G.; Chen, Z.S.; Shchaveleva, I.; Zeng, H.; Kruh, G.D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002, 62, 6172-6177.
32. Le Saux, O.; Urban, Z.; Tschuch, C.; Csiszar, K.; Bacchelli, B.; Quaglino, D.; Pasquali-Ronchetti, I.; Pope, F.M.; Richards, A.; Terry, S.; Bercovitch, L.; de Paepe, A.; Boyd, C.D. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat. Genet. 2000, 25, 223-227.
33. Finger, R.P.; Charbel Issa, P.; Ladewig, M.S.; Gotting, C.; Szliska, C.; Scholl, H.P.; Holz, F.G. Pseudoxanthoma elasticum: Genetics, clinical manifestations and therapeutic approaches. Surv. Ophthalmol. 2009, 54, 272-285.
34. Li, Q.; Jiang, Q.; Pfendner, E.; Varadi, A.; Uitto, J. Pseudoxanthoma elasticum: Clinical phenotypes, molecular genetics and putative pathomechanisms. Exp. Dermatol. 2009, 18, 1-11.
35. Gadsby, D.C.; Vergani, P.; Csanady, L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006, 440, 477-483.
36. Riordan, J.R. CFTR function and prospects for therapy. Annu. Rev. Biochem. 2008, 77, 701-726.
37. Riordan, J.R.; Rommens, J.M.; Kerem, B.; Alon, N.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.; Plavsic, N.; Chou, J.L.; et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989, 245, 1066-1073. (Pubitemid 19231814)
38. Kreindler, J.L. Cystic fibrosis: Exploiting its genetic basis in the hunt for new therapies. Pharmacol. Ther. 2010, 125, 219-229.
39. Rowe, S.M.; Miller, S.; Sorscher, E.J. Cystic fibrosis. N. Engl. J. Med. 2005, 352, 1992-2001. (Pubitemid 40638370)
40. Burke, M.A.; Mutharasan, R.K.; Ardehali, H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ. Res. 2008, 102, 164-176.
41. Olson, T.M.; Terzic, A. Human KATP channelopathies: Diseases of metabolic homeostasis. Pflugers Arch. 2010, 460, 295-306.
42. Aguilar-Bryan, L.; Nichols, C.G.; Wechsler, S.W.; Clement, J.P.t.; Boyd, A.E. 3rd; Gonzalez, G.; Herrera-Sosa, H.; Nguy, K.; Bryan, J.; Nelson, D.A. Cloning of the β-cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 1995, 268, 423-426.
43. James, C.; Kapoor, R.R.; Ismail, D.; Hussain, K. The genetic basis of congenital hyperinsulinism. J. Med. Genet. 2009, 46, 289-299.
44. Gloyn, A.L.; Siddiqui, J.; Ellard, S. Mutations in the genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum. Mutat. 2006, 27, 220-231.
45. Edghill, E.L.; Flanagan, S.E.; Ellard, S. Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11. Rev. Endocr. Metab. Disord. 2010, 11, 193-198.
46. Chen, Z.S.; Hopper-Borge, E.; Belinsky, M.G.; Shchaveleva, I.; Kotova, E.; Kruh, G.D. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol. Pharmacol. 2003, 63, 351-358.
47. Hopper-Borge, E.; Chen, Z.S.; Shchaveleva, I.; Belinsky, M.G.; Kruh, G.D. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel. Cancer Res. 2004, 64, 4927-4930.
48. Guo, Y.; Kotova, E.; Chen, Z.S.; Lee, K.; Hopper-Borge, E.; Belinsky, M.G.; Kruh, G.D. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'- phosphonylmethoxyethyl)adenine. J. Biol. Chem. 2003, 278, 29509-29514.
49. Chen, L.M.; Wu, X.P.; Ruan, J.W.; Liang, Y.J.; Ding, Y.; Shi, Z.; Wang, X.W.; Gu, L.Q.; Fu, L.W. Screening novel, potent multidrug-resistant modulators from imidazole derivatives. Oncol. Res. 2004, 14, 355-362.
50. Kruh, G.D.; Guo, Y.; Hopper-Borge, E.; Belinsky, M.G.; Chen, Z.S. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007, 453, 675-684.
51. Bortfeld, M.; Rius, M.; Konig, J.; Herold-Mende, C.; Nies, A.T.; Keppler, D. Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience 2006, 137, 1247-1257.
52. 4 by human multidrug resistance protein 8 (ABCC11). Mol. Pharmacol. 2005, 67, 545-557.
53. Ono, N.; van der Heijden, I.; Scheffer, G.L.; van de Wetering, K.; van Deemter, E.; de Haas, M.; Boerke, A.; Gadella, B.M.; de Rooij, D.G.; Neefjes, J.J.; Groothuis, T.A.; Oomen, L.; Brocks, L.; Ishikawa, T.; Borst, P. Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm. Biochem. J. 2007, 406, 31-40.
54. Yabuuchi, H.; Takayanagi, S.; Yoshinaga, K.; Taniguchi, N.; Aburatani, H.; Ishikawa, T. ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver. Biochem. Biophys. Res. Commun. 2002, 299, 410-417.
55. Annilo, T.; Dean, M. Degeneration of an ATP-binding cassette transporter gene, ABCC13, in different mammalian lineages. Genomics 2004, 84, 34-46.
56. Bakos, E.; Homolya, L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch. 2007, 453, 621-641.
57. Couture, L.; Nash, J.A.; Turgeon, J. The ATP-binding cassette transporters and their implication in drug disposition: A special look at the heart. Pharmacol. Rev. 2006, 58, 244-258.
58. Deeley, R.G.; Westlake, C.; Cole, S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86, 849-899.
59. Toyoda, Y.; Hagiya, Y.; Adachi, T.; Hoshijima, K.; Kuo, M.T.; Ishikawa, T. MRP class of human ATP binding cassette (ABC) transporters: Historical background and new research directions. Xenobiotica 2008, 38, 833-862.
60. Cole, S.P.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.; Almquist, K.C.; Stewart, A.J.; Kurz, E.U.; Duncan, A.M.; Deeley, R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
61. Slovak, M.L.; Ho, J.P.; Bhardwaj, G.; Kurz, E.U.; Deeley, R.G.; Cole, S.P. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 1993, 53, 3221-3225.
62. Hipfner, D.R.; Almquist, K.C.; Leslie, E.M.; Gerlach, J.H.; Grant, C.E.; Deeley, R.G.; Cole, S.P. Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J. Biol. Chem. 1997, 272, 23623-23630.
63. Godinot, N.; Iversen, P.W.; Tabas, L.; Xia, X.; Williams, D.C.; Dantzig, A.H.; Perry, W.L. 3rd, Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol. Cancer Ther. 2003, 2, 307-316.
64. Ma, L.; Pratt, S.E.; Cao, J.; Dantzig, A.H.; Moore, R.E.; Slapak, C.A. Identification and characterization of the canine multidrug resistance- associated protein. Mol. Cancer Ther. 2002, 1, 1335-1342.
65. Nunoya, K.; Grant, C.E.; Zhang, D.; Cole, S.P.; Deeley, R.G. Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (MRP1). Drug Metab. Dispos. 2003, 31, 1016-1026.
66. Stride, B.D.; Grant, C.E.; Loe, D.W.; Hipfner, D.R.; Cole, S.P.; Deeley, R.G. Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol. Pharmacol. 1997, 52, 344-353.
67. Zhou, S.F.; Wang, L.L.; Di, Y.M.; Xue, C.C.; Duan, W.; Li, C.G.; Li, Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem. 2008, 15, 1981-2039.
68. Deeley, R.G.; Cole, S.P. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett. 2006, 580, 1103-1111.
69. Chang, X.B. A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev. 2007, 26, 15-37.
70. Conseil, G.; Deeley, R.G.; Cole, S.P. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet. Genomics 2005, 15, 523-533.
71. Liu, Y.H.; Di, Y.M.; Zhou, Z.W.; Mo, S.L.; Zhou, S.F. Multidrug resistance-associated proteins and implications in drug development. Clin. Exp. Pharmacol. Physiol. 2010, 37, 115-120.
72. Zhou, S.F. Role of multidrug resistance associated proteins in drug development. Drug Discov. Ther. 2008, 2, 305-332.
73. Ueda, K.; Cardarelli, C.; Gottesman, M.M.; Pastan, I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 3004-3008.
74. Zhou, S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition Xenobiotica 2008, 38, 802-832.
75. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
76. Mirski, S.E.; Gerlach, J.H.; Cole, S.P. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 1987, 47, 2594-2598.
77. McGrath, T.; Center, M.S. Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. Biochem. Biophys. Res. Commun. 1987, 145, 1171-1176.
78. Cole, S.P. Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother. Pharmacol. 1990, 26, 250-256.
79. Cole, S.P.; Downes, H.F.; Mirski, S.E.; Clements, D.J. Alterations in glutathione and glutathione-related enzymes in a multidrugresistant small cell lung cancer cell line. Mol. Pharmacol. 1990, 37, 192-197.
80. Cole, S.P.; Sparks, K.E.; Fraser, K.; Loe, D.W.; Grant, C.E.; Wilson, G.M.; Deeley, R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 1994, 54, 5902-5910.
81. Cole, S.P.; Downes, H.F.; Slovak, M.L. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br. J. Cancer 1989, 59, 42-46.
82. Cole, S.P.; Chanda, E.R.; Dicke, F.P.; Gerlach, J.H.; Mirski, S.E. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to druginduced DNA damage and reduced levels of topoisomerase II. Cancer Res. 1991, 51, 3345-3352.
83. Almquist, K.C.; Loe, D.W.; Hipfner, D.R.; Mackie, J.E.; Cole, S.P.; Deeley, R.G. Characterization of the Mr 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cell. Cancer Res. 1995, 55, 102-110.
84. Flens, M.J.; Izquierdo, M.A.; Scheffer, G.L.; Fritz, J.M.; Meijer, C.J.; Scheper, R.J.; Zaman, G.J. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrugresistant tumor cells by monoclonal antibodies. Cancer Res. 1994, 54, 4557-4563.
85. Zaman, G.J.; Flens, M.J.; van Leusden, M.R.; de Haas, M.; Mulder, H.S.; Lankelma, J.; Pinedo, H.M.; Scheper, R.J.; Baas, F.; Broxterman, H.J.; et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 8822-8826.
86. Grant, C.E.; Valdimarsson, G.; Hipfner, D.R.; Almquist, K.C.; Cole, S.P.; Deeley, R.G. Overexpression of multidrug resistanceassociated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994, 54, 357-361.
87. 4 and structurally related conjugates. J. Biol. Chem. 1994, 269, 27807-27810.
88. Muller, M.; Meijer, C.; Zaman, G.J.; Borst, P.; Scheper, R.J.; Mulder, N.H.; de Vries, E.G.; Jansen, P.L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 13033-13037.
89. Leier, I.; Jedlitschky, G.; Buchholz, U.; Center, M.; Cole, S.P.; Deeley, R.G.; Keppler, D. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem. J. 1996, 314 (Pt 2), 433-437. (Pubitemid 26075650)
90. Zaman, G.J.; Versantvoort, C.H.; Smit, J.J.; Eijdems, E.W.; de Haas, M.; Smith, A.J.; Broxterman, H.J.; Mulder, N.H.; de Vries, E.G.; Baas, F. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993, 53, 1747-1750.
91. Burger, H.; Nooter, K.; Zaman, G.J.; Sonneveld, P.; van Wingerden, K.E.; Oostrum, R.G.; Stoter, G. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994, 8, 990-997. (Pubitemid 24181302)
92. Giraud, C.; Manceau, S.; Treluyer, J.M. ABC transporters in human lymphocytes: Expression, activity and role, modulating factors and consequences for antiretroviral therapies. Expert Opin. Drug Metab. Toxicol. 2010, 6, 571-589.
93. Aye, I.L.; Paxton, J.W.; Evseenko, D.A.; Keelan, J.A. Expression, localisation and activity of ATP binding cassette (ABC) family of drug transporters in human amnion membranes. Placenta 2007, 28, 868-877.
94. Bosquillon, C. Drug transporters in the lung-do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 2010, 99, 2240-2255.
95. Dallas, S.; Miller, D.S.; Bendayan, R. Multidrug resistanceassociated proteins: Expression and function in the central nervous system. Pharmacol. Rev. 2006, 58, 140-161.
96. Shen, S.; Zhang, W. ABC transporters and drug efflux at the bloodbrain barrier. Rev. Neurosci. 2010, 21, 29-53.
97. Miller, D.S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci. 2010, 31, 246-254.
98. Roelofsen, H.; Vos, T.A.; Schippers, I.J.; Kuipers, F.; Koning, H.; Moshage, H.; Jansen, P.L.; Muller, M. Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 1997, 112, 511-521.
99. Taguchi, Y.; Saeki, K.; Komano, T. Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002, 521, 211-213.
100. Stride, B.D.; Valdimarsson, G.; Gerlach, J.H.; Wilson, G.M.; Cole, S.P.; Deeley, R.G. Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol. Pharmacol. 1996, 49, 962-971.
101. Conrad, S.; Viertelhaus, A.; Orzechowski, A.; Hoogstraate, J.; Gjellan, K.; Schrenk, D.; Kauffmann, H.M. Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology 2001, 156, 81-91.
102. Flens, M.J.; Zaman, G.J.R.; van der Valk, P.; Izquierdo, M.A.; Schroeijers, A.B.; Scheffer, G.L.; van der Groep, P.; de Haas, M.; Meijer, C.J.L.M.; Scheper, R.J. Tissue distribution of the multidrug resistance protein. Am. J. Pathol. 1996, 148, 1237-1247. (Pubitemid 26111082)
103. Maher, J.M.; Slitt, A.L.; Cherrington, N.J.; Cheng, X.; Klaassen, C.D. Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab. Dispos. 2005, 33, 947-955.
104. Wijnholds, J.; Scheffer, G.L.; van der Valk, M.; van der Valk, P.; Beijnen, J.H.; Scheper, R.J.; Borst, P. Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J .Exp. Med. 1998, 188, 797-808.
105. Qian, Y.M.; Song, W.C.; Cui, H.; Cole, S.P.; Deeley, R.G. Glutathione stimulates sulfated estrogen transport by multidrug resistance protein 1. J. Biol. Chem. 2001, 276, 6404-6411.
106. Becker, U.; Ehrhardt, C.; Daum, N.; Baldes, C.; Schaefer, U.F.; Ruprecht, K.W.; Kim, K.J.; Lehr, C.M. Expression of ABCtransporters in human corneal tissue and the transformed cell line, HCE-T. J. Ocul. Pharmacol. Ther. 2007, 23, 172-181.
107. Yang, J.J.; Ann, D.K.; Kannan, R.; Lee, V.H. Multidrug resistance protein 1 (MRP1) in rabbit conjunctival epithelial cells: Its effect on drug efflux and its regulation by adenoviral infection. Pharm. Res. 2007, 24, 1490-500.
108. Mayer, R.; Kartenbeck, J.; Buchler, M.; Jedlitschky, G.; Leier, I.; Keppler, D. Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J. Cell. Biol. 1995, 131, 137-150.
109. Peng, K.C.; Cluzeaud, F.; Bens, M.; Van Huyen, J.P.; Wioland, M.A.; Lacave, R.; Vandewalle, A. Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J. Histochem. Cytochem. 1999, 47, 757-768.
110. Pei, Q.L.; Kobayashi, Y.; Tanaka, Y.; Taguchi, Y.; Higuchi, K.; Kaito, M.; Ma, N.; Semba, R.; Kamisako, T.; Adachi, Y. Increased expression of multidrug resistance-associated protein 1 (MRP1) in hepatocyte basolateral membrane and renal tubular epithelia after bile duct ligation in rats. Hepatol. Res. 2002, 22, 58-64.
111. Scheffer, G.L.; Pijnenborg, A.C.; Smit, E.F.; Muller, M.; Postma, D.S.; Timens, W.; van der Valk, P.; de Vries, E.G.; Scheper, R.J. Multidrug resistance related molecules in human and murine lung. J. Clin. Pathol. 2002, 55, 332-339.
112. St-Pierre, M.V.; Serrano, M.A.; Macias, R.I.; Dubs, U.; Hoechli, M.; Lauper, U.; Meier, P.J.; Marin, J.J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279, R1495- 1503.
113. Zhang, Y.; Schuetz, J.D.; Elmquist, W.F.; Miller, D.W. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J. Pharmacol. Exp. Ther. 2004, 311, 449-455.
114. Hipfner, D.R.; Gauldie, S.D.; Deeley, R.G.; Cole, S.P. Detection of the Mr 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 1994, 54, 5788-5792.
115. Westlake, C.J.; Cole, S.P.; Deeley, R.G. Role of the NH2-terminal membrane spanning domain of multidrug resistance protein 1/ABCC1 in protein processing and trafficking. Mol. Biol. Cell 2005, 16, 2483-2492.
116. Van Luyn, M.J.; Muller, M.; Renes, J.; Meijer, C.; Scheper, R.J.; Nienhuis, E.F.; Mulder, N.H.; Jansen, P.L.; De Vries, E.G. Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1. Int. J. Cancer 1998, 76, 55-62.
117. Rajagopal, A.; Simon, S.M. Subcellular localization and activity of multidrug resistance proteins. Mol. Biol. Cell 2003, 14, 3389-3399.
118. Gennuso, F.; Fernetti, C.; Tirolo, C.; Testa, N.; L'Episcopo, F.; Caniglia, S.; Morale, M.C.; Ostrow, J.D.; Pascolo, L.; Tiribelli, C.; Marchetti, B. Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistanceassociated protein 1 (Mrp1). Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 2470-2475.
119. Wioland, M.A.; Fleury-Feith, J.; Corlieu, P.; Commo, F.; Monceaux, G.; Lacau-St-Guily, J.; Bernaudin, J.F. CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. J. Histochem. Cytochem. 2000, 48, 1215-1222.
120. Bakos, E.; Hegedus, T.; Hollo, Z.; Welker, E.; Tusnady, G.E.; Zaman, G.J.; Flens, M.J.; Varadi, A.; Sarkadi, B. Membrane topology and glycosylation of the human multidrug resistanceassociated protein. J. Biol. Chem. 1996, 271, 12322-12326.
121. Bakos, E.; Evers, R.; Calenda, G.; Tusnady, G.E.; Szakacs, G.; Varadi, A.; Sarkadi, B. Characterization of the amino-terminal regions in the human multidrug resistance protein (MRP1). J. Cell Sci. 2000, 113 Pt 24, 4451-4461. (Pubitemid 32117906)
122. Westlake, C.J.; Qian, Y.M.; Gao, M.; Vasa, M.; Cole, S.P.; Deeley, R.G. Identification of the structural and functional boundaries of the multidrug resistance protein 1 cytoplasmic loop 3. Biochemistry 2003, 42, 14099-14113.
123. Slapak, C.A.; Fracasso, P.M.; Martell, R.L.; Toppmeyer, D.L.; Lecerf, J.M.; Levy, S.B. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res. 1994, 54, 5607-5613.
124. Morrow, C.S.; Smitherman, P.K.; Diah, S.K.; Schneider, E.; Townsend, A.J. Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification. Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J. Biol. Chem. 1998, 273, 20114-20120.
125. Morrow, C.S.; Peklak-Scott, C.; Bishwokarma, B.; Kute, T.E.; Smitherman, P.K.; Townsend, A.J. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol. Pharmacol. 2006, 69, 1499-1505.
126. Zaman, G.J.; Lankelma, J.; van Tellingen, O.; Beijnen, J.; Dekker, H.; Paulusma, C.; Oude Elferink, R.P.; Baas, F.; Borst, P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 7690-7694.
127. 4 transport mediated by MRP/GS-X pump. Biochem. Biophys. Res. Commun. 1998, 247, 859-863.
128. Sakamoto, H.; Hara, H.; Hirano, K.; Adachi, T. Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells. Cancer Lett. 1999, 135, 113-119.
129. Hooijberg, J.H.; Peters, G.J.; Assaraf, Y.G.; Kathmann, I.; Priest, D.G.; Bunni, M.A.; Veerman, A.J.; Scheffer, G.L.; Kaspers, G.J.; Jansen, G. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol. 2003, 65, 765-771.
130. Hooijberg, J.H.; Broxterman, H.J.; Kool, M.; Assaraf, Y.G.; Peters, G.J.; Noordhuis, P.; Scheper, R.J.; Borst, P.; Pinedo, H.M.; Jansen, G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999, 59, 2532-2535.
131. Assaraf, Y.G.; Rothem, L.; Hooijberg, J.H.; Stark, M.; Ifergan, I.; Kathmann, I.; Dijkmans, B.A.; Peters, G.J.; Jansen, G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 2003, 278, 6680-6686.
132. Zeng, H.; Chen, Z.S.; Belinsky, M.G.; Rea, P.A.; Kruh, G.D. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: Effect of polyglutamylation on MTX transport. Cancer Res. 2001, 61, 7225-7232.
133. Chu, X.Y.; Suzuki, H.; Ueda, K.; Kato, Y.; Akiyama, S.; Sugiyama, Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J. Pharmacol. Exp. Ther. 1999, 288, 735-741.
134. Paumi, C.M.; Ledford, B.G.; Smitherman, P.K.; Townsend, A.J.; Morrow, C.S. Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity. J. Biol. Chem. 2001, 276, 7952-7956.
135. Barnouin, K.; Leier, I.; Jedlitschky, G.; Pourtier-Manzanedo, A.; Konig, J.; Lehmann, W.D.; Keppler, D. Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br. J. Cancer 1998, 77, 201-209. (Pubitemid 28029535)
136. Glisson, B.; Gupta, R.; Hodges, P.; Ross, W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: Evidence for a common intracellular target. Cancer Res. 1986, 46, 1939-1942.
137. Breuninger, L.M.; Paul, S.; Gaughan, K.; Miki, T.; Chan, A.; Aaronson, S.A.; Kruh, G.D. Expression of multidrug resistanceassociated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995, 55, 5342-5347.
138. Schneider, E.; Horton, J.K.; Yang, C.H.; Nakagawa, M.; Cowan, K.H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 1994, 54, 152-158.
139. Diah, S.K.; Smitherman, P.K.; Aldridge, J.; Volk, E.L.; Schneider, E.; Townsend, A.J.; Morrow, C.S. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: Evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 2001, 61, 5461-5467.
140. Grzywacz, M.J.; Yang, J.M.; Hait, W.N. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res. 2003, 63, 2492-2498.
141. Rochat, B.; Morsman, J.M.; Murray, G.I.; Figg, W.D.; McLeod, H.L. Human CYP1B1 and anticancer agent metabolism: Mechanism for tumor-specific drug inactivation? J. Pharmacol. Exp. Ther. 2001, 296, 537-541.
142. Shet, M.S.; McPhaul, M.; Fisher, C.W.; Stallings, N.R.; Estabrook, R.W. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab. Dispos. 1997, 25, 1298-1303.
143. de Jong, M.C.; Slootstra, J.W.; Scheffer, G.L.; Schroeijers, A.B.; Puijk, W.C.; Dinkelberg, R.; Kool, M.; Broxterman, H.J.; Meloen, R.H.; Scheper, R.J. Peptide transport by the multidrug resistance protein MRP1. Cancer Res. 2001, 61, 2552-2557.
144. Williams, G.C.; Liu, A.; Knipp, G.; Sinko, P.J. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother. 2002, 46, 3456-3462.
145. Srinivas, R.V.; Middlemas, D.; Flynn, P.; Fridland, A. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob. Agents Chemother. 1998, 42, 3157-3162.
146. Jones, K.; Bray, P.G.; Khoo, S.H.; Davey, R.A.; Meaden, E.R.; Ward, S.A.; Back, D.J. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance? Aids 2001, 15, 1353-1358.
147. Huisman, M.T.; Smit, J.W.; Wiltshire, H.R.; Hoetelmans, R.M.; Beijnen, J.H.; Schinkel, A.H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 2001, 59, 806-813.
148. Kim, R.B.; Fromm, M.F.; Wandel, C.; Leake, B.; Wood, A.J.; Roden, D.M.; Wilkinson, G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101, 289-294.
149. Park, S.; Sinko, P.J. P-glycoprotein and mutlidrug resistanceassociated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 2005, 312, 1249-1256.
150. Polli, J.W.; Jarrett, J.L.; Studenberg, S.D.; Humphreys, J.E.; Dennis, S.W.; Brouwer, K.R.; Woolley, J.L. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 1999, 16, 1206-1212.
151. van der Sandt, I.C.; Vos, C.M.; Nabulsi, L.; Blom-Roosemalen, M.C.; Voorwinden, H.H.; de Boer, A.G.; Breimer, D.D. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. Aids 2001, 15, 483-491.
152. Meaden, E.R.; Hoggard, P.G.; Newton, P.; Tjia, J.F.; Aldam, D.; Cornforth, D.; Lloyd, J.; Williams, I.; Back, D.J.; Khoo, S.H. Pglycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J. Antimicrob. Chemother. 2002, 50, 583-588.
153. Vezmar, M.; Georges, E. Direct binding of chloroquine to the multidrug resistance protein (MRP): Possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem. Pharmacol. 1998, 56, 733-742.
154. Shitan, N.; Tanaka, M.; Terai, K.; Ueda, K.; Yazaki, K. Human MDR1 and MRP1 recognize berberine as their transport substrate. Biosci. Biotechnol. Biochem. 2007, 71, 242-245.
155. Yu, X.Y.; Lin, S.G.; Chen, X.; Zhou, Z.W.; Liang, J.; Duan, W.; Chowbay, B.; Wen, J.Y.; Chan, E.; Cao, J.; Li, C.G.; Zhou, S.F. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Curr. Drug Metab. 2007, 8, 365-378.
156. Yu, X.Y.; Lin, S.G.; Zhou, Z.W.; Chen, X.; Liang, J.; Liu, P.Q.; Duan, W.; Chowbay, B.; Wen, J.Y.; Li, C.G.; Zhou, S.F. Role of Pglycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge. Curr. Drug Metab. 2007, 8, 325-340. (Pubitemid 46780062)
157. Yu, X.Y.; Zhou, Z.W.; Lin, S.G.; Chen, X.; Yu, X.Q.; Liang, J.; Duan, W.; Wen, J.Y.; Li, X.T.; Zhou, S.F. Role of ATP-binding cassette drug transporters in the intestinal absorption of tanshinone IIB, one of the major active diterpenoids from the root of Salvia miltiorrhiza. Xenobiotica 2007, 37, 375-415. (Pubitemid 46572883)
158. Zhang, J.; Huang, M.; Guan, S.; Bi, H.C.; Pan, Y.; Duan, W.; Chan, S.Y.; Chen, X.; Hong, Y.H.; Bian, J.S.; Yang, H.Y.; Zhou, S. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. J. Pharmacol. Exp. Ther. 2006, 317, 1285-1294.
159. Chen, X.; Zhou, Z.W.; Xue, C.C.; Li, X.X.; Zhou, S.F. Role of Pglycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier. Xenobiotica 2007, 37, 635-678.
160. Zhou, Z.W.; Chen, X.; Liang, J.; Yu, X.Y.; Wen, J.W.; Zhou, S.F. Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the roots of Salvia miltiorrhiza, across the blood-brain barrier. Drug Metab. Lett. 2007, 1, 205-217.
161. Zhou, L.; Zuo, Z.; Chow, M.S. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 2005, 45, 1345-1359.
162. Hendrikse, N.H.; Kuipers, F.; Meijer, C.; Havinga, R.; Bijleveld, C.M.; van der Graaf, W.T.; Vaalburg, W.; de Vries, E.G. In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. Cancer Chemother. Pharmacol. 2004, 54, 131-138.
163. Chen, W.S.; Luker, K.E.; Dahlheimer, J.L.; Pica, C.M.; Luker, G.D.; Piwnica-Worms, D. Effects of MDR1 and MDR3 Pglycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of 99mTc-tetrofosmin. Biochem. Pharmacol. 2000, 60, 413-426.
164. Lorusso, V.; Pascolo, L.; Fernetti, C.; Visigalli, M.; Anelli, P.; Tiribelli, C. In vitro and in vivo hepatic transport of the magnetic resonance imaging contrast agent B22956/1: Role of MRP proteins. Biochem. Biophys. Res. Commun. 2002, 293, 100-105.
165. Leslie, E.M.; Haimeur, A.; Waalkes, M.P. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 2004, 279, 32700-32708.
166. Ito, K.; Olsen, S.L.; Qiu, W.; Deeley, R.G.; Cole, S.P. Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J. Biol. Chem. 2001, 276, 15616-15624.
167. Salerno, M.; Petroutsa, M.; Garnier-Suillerot, A. The MRP1- mediated effluxes of arsenic and antimony do not require arsenicglutathione and antimony-glutathione complex formation. J. Bioenerg. Biomembr. 2002, 34, 135-145.
168. Lorico, A.; Bertola, A.; Baum, C.; Fodstad, O.; Rappa, G. Role of the multidrug resistance protein 1 in protection from heavy metal oxyanions: Investigations in vitro and in MRP1-deficient mice. Biochem. Biophys. Res. Commun. 2002, 291, 617-622.
169. Liu, J.; Chen, H.; Miller, D.S.; Saavedra, J.E.; Keefer, L.K.; Johnson, D.R.; Klaassen, C.D.; Waalkes, M.P. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol. Pharmacol. 2001, 60, 302-309.
170. Lorico, A.; Rappa, G.; Flavell, R.A.; Sartorelli, A.C. Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res. 1996, 56, 5351-5355.
171. Leslie, E.M.; Letourneau, I.J.; Deeley, R.G.; Cole, S.P. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 2003, 42, 5214-5224.
172. Loe, D.W.; Stewart, R.K.; Massey, T.E.; Deeley, R.G.; Cole, S.P. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol. Pharmacol. 1997, 51, 1034-1041.
173. Lorico, A.; Nesland, J.; Emilsen, E.; Fodstad, O.; Rappa, G. Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: Investigations using Mrp1-null mice. Toxicology 2002, 171, 201-205. (Pubitemid 34142493)
174. Geisler, M.; Girin, M.; Brandt, S.; Vincenzetti, V.; Plaza, S.; Paris, N.; Kobae, Y.; Maeshima, M.; Billion, K.; Kolukisaoglu, U.H.; Schulz, B.; Martinoia, E. Arabidopsis immunophilin-like TWD1 functionally interacts with vacuolar ABC transporters. Mol. Biol. Cell 2004, 15, 3393-3405.
175. Diah, S.K.; Smitherman, P.K.; Townsend, A.J.; Morrow, C.S. Detoxification of 1-chloro-2,4-dinitrobenzene in MCF7 breast cancer cells expressing glutathione S-transferase P1-1 and/or multidrug resistance protein 1. Toxicol. Appl. Pharmacol. 1999, 157, 85-93.
176. Morrow, C.S.; Diah, S.; Smitherman, P.K.; Schneider, E.; Townsend, A.J. Multidrug resistance protein and glutathione Stransferase P1-1 act in synergy to confer protection from 4- nitroquinoline 1-oxide toxicity. Carcinogenesis 1998, 19, 109-115.
177. Leslie, E.M.; Ito, K.; Upadhyaya, P.; Hecht, S.S.; Deeley, R.G.; Cole, S.P. Transport of the β-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J. Biol. Chem. 2001, 276, 27846-27854.
178. Jedlitschky, G.; Leier, I.; Buchholz, U.; Center, M.; Keppler, D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 1994, 54, 4833-4836.
179. Saengkhae, C.; Loetchutinat, C.; Garnier-Suillerot, A. Kinetic analysis of fluorescein and dihydrofluorescein effluxes in tumour cells expressing the multidrug resistance protein, MRP1. Biochem. Pharmacol. 2003, 65, 969-977.
180. Saengkhae, C.; Loetchutinat, C.; Garnier-Suillerot, A. Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1). Biophys. J. 2003, 85, 2006-2014.
181. Olson, D.P.; Taylor, B.J.; Ivy, S.P. Detection of MRP functional activity: Calcein AM but not BCECF AM as a multidrug resistancerelated protein (MRP1) substrate. Cytometry 2001, 46, 105-113.
182. Bagrij, T.; Klokouzas, A.; Hladky, S.B.; Barrand, M.A. Influences of glutathione on anionic substrate efflux in tumour cells expressing the multidrug resistance-associated protein, MRP1. Biochem. Pharmacol. 2001, 62, 199-206.
183. Salvi, A.; Quillan, J.M.; Sadee, W. Monitoring intracellular pH changes in response to osmotic stress and membrane transport activity using 5-chloromethylfluorescein. AAPS Pharm. Sci. 2002, 4, E21.
184. Prechtl, S.; Roellinghoff, M.; Scheper, R.; Cole, S.P.; Deeley, R.G.; Lohoff, M. The multidrug resistance protein 1: A functionally important activation marker for murine Th1 cells. J. Immunol. 2000, 164, 754-761.
185. Keppler, D.; Cui, Y.; Konig, J.; Leier, I.; Nies, A. Export pumps for anionic conjugates encoded by MRP genes. Adv. Enzyme Regul. 1999, 39, 237-246.
186. Dogan, A.L.; Legrand, O.; Faussat, A.M.; Perrot, J.Y.; Marie, J.P. Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines. Leuk. Res. 2004, 28, 619-622.
187. Rigato, I.; Pascolo, L.; Fernetti, C.; Ostrow, J.D.; Tiribelli, C. The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin. Biochem. J. 2004, 383, 335-341.
188. Evers, R.; Cnubben, N.H.; Wijnholds, J.; van Deemter, L.; van Bladeren, P.J.; Borst, P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 1997, 419, 112-116.
189. Akimaru, K.; Kuo, M.T.; Furuta, K.; Suzuki, M.; Noyori, R.; Ishikawa, T. Induction of MRP/GS-X pump and cellular resistance to anticancer prostaglandins. Cytotechnology 1996, 19, 221-227.
190. Loe, D.W.; Almquist, K.C.; Cole, S.P.; Deeley, R.G. ATPdependent 17 β-estradiol 17-(β-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J. Biol. Chem. 1996, 271, 9683-9689.
191. 4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem. 1996, 271, 9675-9682.
192. Loe, D.W.; Deeley, R.G.; Cole, S.P. Characterization of vincristine transport by the Mr 190,000 multidrug resistance protein (MRP): Evidence for cotransport with reduced glutathione. Cancer Res. 1998, 58, 5130-5136.
193. Garnier-Suillerot, A.; Marbeuf-Gueye, C.; Salerno, M.; Loetchutinat, C.; Fokt, I.; Krawczyk, M.; Kowalczyk, T.; Priebe, W. Analysis of drug transport kinetics in multidrug-resistant cells: Implications for drug action. Curr. Med. Chem. 2001, 8, 51-64.
194. Lorico, A.; Rappa, G.; Finch, R.A.; Yang, D.; Flavell, R.A.; Sartorelli, A.C. Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res. 1997, 57, 5238-5242.
195. Falcao, A.S.; Bellarosa, C.; Fernandes, A.; Brito, M.A.; Silva, R.F.; Tiribelli, C.; Brites, D. Role of multidrug resistance-associated protein 1 expression in the in vitro susceptibility of rat nerve cell to unconjugated bilirubin. Neuroscience 2007, 144, 878-888.
196. Pascolo, L.; Fernetti, C.; Garcia-Mediavilla, M.V.; Ostrow, J.D.; Tiribelli, C. Mechanisms for the transport of unconjugated bilirubin in human trophoblastic BeWo cells. FEBS Lett. 2001, 495, 94-99.
197. Renes, J.; de Vries, E.E.; Hooiveld, G.J.; Krikken, I.; Jansen, P.L.; Muller, M. Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem. J. 2000, 350(Pt 2), 555-561.
198. Loe, D.W.; Deeley, R.G.; Cole, S.P. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer 1996, 32A, 945-957.
199. Lautier, D.; Canitrot, Y.; Deeley, R.G.; Cole, S.P. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol. 1996, 52, 967-977.
200. Mickisch, G.H.; Merlino, G.T.; Galski, H.; Gottesman, M.M.; Pastan, I. Transgenic mice that express the human multidrugresistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc. Natl. Acad. Sci. U. S. A. 1991, 88, 547-551.
201. Wright, S.R.; Boag, A.H.; Valdimarsson, G.; Hipfner, D.R.; Campling, B.G.; Cole, S.P.; Deeley, R.G. Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin. Cancer Res. 1998, 4, 2279-2289.
202. Banks, W.A. Physiology and pathology of the blood-brain barrier: Implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J. Neurovirol. 1999, 5, 538-555.
203. Loscher, W.; Potschka, H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005, 2, 86-98.
204. Girardin, F. Membrane transporter proteins: A challenge for CNS drug development. Dialogues Clin. Neurosci. 2006, 8, 311-321.
205. de Boer, A.G.; Gaillard, P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 323-355.
206. Wijnholds, J.; deLange, E.C.; Scheffer, G.L.; van den Berg, D.J.; Mol, C.A.; van der Valk, M.; Schinkel, A.H.; Scheper, R.J.; Breimer, D.D.; Borst, P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the bloodcerebrospinal fluid barrier. J. Clin. Invest. 2000, 105, 279-285.
207. Johnson, D.R.; Finch, R.A.; Lin, Z.P.; Zeiss, C.J.; Sartorelli, A.C. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res. 2001, 61, 1469-1476.
208. Wijnholds, J.; Evers, R.; van Leusden, M.R.; Mol, C.A.; Zaman, G.J.; Mayer, U.; Beijnen, J.H.; van der Valk, M.; Krimpenfort, P.; Borst, P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistanceassociated protein. Nat. Med. 1997, 3, 1275-1279.
209. 4 transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000, 103, 757-768.
210. Schultz, M.J.; Wijnholds, J.; Peppelenbosch, M.P.; Vervoordeldonk, M.J.; Speelman, P.; van Deventer, S.J.; Borst, P.; van der Poll, T. Mice lacking the multidrug resistance protein 1 are resistant to Streptococcus pneumoniae-induced pneumonia. J. Immunol. 2001, 166, 4059-4064.
211. Verbon, A.; Leemans, J.C.; Weijer, S.; Florquin, S.; Van Der Poll, T. Mice lacking the multidrug resistance protein 1 have a transiently impaired immune response during tuberculosis. Clin. Exp. Immunol. 2002, 130, 32-36.
212. Yang, Z.; Horn, M.; Wang, J.; Shen, D.D.; Ho, R.J. Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS Pharm. Sci. 2004, 6, E8.
213. Zhang, D.W.; Cole, S.P.; Deeley, R.G. Identification of a nonconserved amino acid residue in multidrug resistance protein 1 important for determining substrate specificity: Evidence for functional interaction between transmembrane helices 14 and 17. J. Biol. Chem. 2001, 276, 34966-34974.
214. Yang, A.K.; Zhou, Z.W.; Wei, M.Q.; Liu, J.P.; Zhou, S.F. Modulators of multidrug resistance associated proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases. Curr. Top. Med. Chem. 2010, 10, 1732-1756.
215. Boumendjel, A.; Baubichon-Cortay, H.; Trompier, D.; Perrotton, T.; Di Pietro, A. Anticancer multidrug resistance mediated by MRP1: Recent advances in the discovery of reversal agents. Med. Res. Rev. 2005, 25, 453-472.
216. Lee, C.H. Reversing agents for ATP-binding cassette drug transporters. Methods Mol. Biol. 2010, 596, 325-340.
217. Gollapudi, S.; Kim, C.H.; Tran, B.N.; Sangha, S.; Gupta, S. Probenecid reverses multidrug resistance in multidrug resistanceassociated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein- overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother. Pharmacol. 1997, 40, 150-158.
218. Draper, M.P.; Martell, R.L.; Levy, S.B. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer 1997, 75, 810-815.
219. Bakos, E.; Evers, R.; Sinko, E.; Varadi, A.; Borst, P.; Sarkadi, B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 2000, 57, 760-768.
220. Evers, R.; Kool, M.; van Deemter, L.; Janssen, H.; Calafat, J.; Oomen, L.C.; Paulusma, C.C.; Oude Elferink, R.P.; Baas, F.; Schinkel, A.H.; Borst, P. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest. 1998, 101, 1310-1319.
221. Stamp, L.K.; O'Donnell, J.L.; Chapman, P.T. Emerging therapies in the long-term management of hyperuricaemia and gout. Intern. Med. J. 2007, 37, 258-266.
222. Evers, R.; de Haas, M.; Sparidans, R.; Beijnen, J.; Wielinga, P.R.; Lankelma, J.; Borst, P. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer 2000, 83, 375-383.
223. Jones, T.R.; Zamboni, R.; Belley, M.; Champion, E.; Charette, L.; Ford-Hutchinson, A.W.; Frenette, R.; Gauthier, J.Y.; Leger, S.; Masson, P.; McFarlane, C.S.; Piechuta, H.; Rokach, J.; Williams, H.; Young, R.N.; de Haven, R.N.; Pong, S.S. Pharmacology of L- 660,711 (MK-571): A novel potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol. 1989, 67, 17-28. (Pubitemid 19068107)
224. Gekeler, V.; Ise, W.; Sanders, K.H.; Ulrich, W.R.; Beck, J. The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem. Biophys. Res. Commun. 1995, 208, 345-352.
225. Tian, Q.; Zhang, J.; Chan, E.; Duan, W.; Zhou, S.F. Multidrug resistance proteins (MRPs) and implication in drug development. Drug Dev. Res. 2005, 51, 1-18.
226. Tian, Q.; Zhang, J.; Chan, S.Y.; Tan, T.M.; Duan, W.; Huang, M.; Zhu, Y.Z.; Chan, E.; Yu, Q.; Nie, Y.Q.; Ho, P.C.; Li, Q.; Ng, K.Y.; Yang, H.Y.; Wei, H.; Bian, J.S.; Zhou, S.F. Topotecan is a substrate for multidrug resistance associated protein 4. Curr. Drug Metab. 2006, 7, 105-118.
227. Tian, Q.; Zhang, J.; Tan, T.M.; Chan, E.; Duan, W.; Chan, S.Y.; Boelsterli, U.A.; Ho, P.C.; Yang, H.; Bian, J.S.; Huang, M.; Zhu, Y.Z.; Xiong, W.; Li, X.; Zhou, S. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res. 2005, 22, 1837-1853.
228. 4 efflux in lung cancer cells expressing multidrug resistance protein. Biochem. Biophys. Res. Commun. 1998, 251, 307-312.
229. Duffy, C.P.; Elliott, C.J.; O'Connor, R.A.; Heenan, M.M.; Coyle, S.; Cleary, I.M.; Kavanagh, K.; Verhaegen, S.; O'Loughlin, C.M.; NicAmhlaoibh, R.; Clynes, M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of nonsteroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer 1998, 34, 1250-1259.
230. Mano, Y.; Usui, T.; Kamimura, H. Contribution of UDPglucuronosyltransferases 1A9 and 2B7 to the glucuronidation of indomethacin in the human liver. Eur. J. Clin. Pharmacol. 2007, 63, 289-296. (Pubitemid 46233157)
231. Kuehl, G.E.; Lampe, J.W.; Potter, J.D.; Bigler, J. Glucuronidation of nonsteroidal anti-inflammatory drugs: Identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos. 2005, 33, 1027-1035.
232. Barrand, M.A.; Rhodes, T.; Center, M.S.; Twentyman, P.R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from Pglycoprotein. Eur. J. Cancer 1993, 29A, 408-415.
233. Hooijberg, J.H.; Broxterman, H.J.; Heijn, M.; Fles, D.L.; Lankelma, J.; Pinedo, H.M. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett. 1997, 413, 344-348.
234. Hooijberg, J.H.; Broxterman, H.J.; Scheffer, G.L.; Vrasdonk, C.; Heijn, M.; de Jong, M.C.; Scheper, R.J.; Lankelma, J.; Pinedo, H.M. Potent interaction of flavopiridol with MRP1. Br. J. Cancer 1999, 81, 269-276.
235. Versantvoort, C.H.; Broxterman, H.J.; Lankelma, J.; Feller, N.; Pinedo, H.M. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem. Pharmacol. 1994, 48, 1129-1136.
236. Nguyen, H.; Zhang, S.; Morris, M.E. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci. 2003, 92, 250-257.
237. Marbeuf-Gueye, C.; Salerno, M.; Quidu, P.; Garnier-Suillerot, A. Inhibition of the P-glycoprotein- and multidrug resistance proteinmediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P. Eur. J. Pharmacol. 2000, 391, 207-216.
238. Aoki, S.; Chen, Z.S.; Higasiyama, K.; Setiawan, A.; Akiyama, S.; Kobayashi, M. Reversing effect of agosterol A, a spongean sterol acetate, on multidrug resistance in human carcinoma cells. Jpn. J. Cancer Res. 2001, 92, 886-895.
239. Chen, Z.S.; Aoki, S.; Komatsu, M.; Ueda, K.; Sumizawa, T.; Furukawa, T.; Okumura, H.; Ren, X.Q.; Belinsky, M.G.; Lee, K.; Kruh, G.D.; Kobayashi, M.; Akiyama, S. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int. J. Cancer. 2001, 93, 107-113.
240. Bichat, F.; Solis-Recendez, G.; Poullain, M.G.; Poupon, M.F.; Khayat, D.; Bastian, G. S9788 modulation of P-glycoprotein- and multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells. Biochem. Pharmacol. 1998, 56, 497-502.
241. Germann, U.A.; Ford, P.J.; Shlyakhter, D.; Mason, V.S.; Harding, M.W. Chemosensitization and drug accumulation effects of VX- 710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997, 8, 141-155.
242. Minderman, H.; O'Loughlin, K.L.; Pendyala, L.; Baer, M.R. VX- 710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin. Cancer Res. 2004, 10, 1826-1834.
243. Bandi, N.; Kompella, U.B. Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur. J. Pharmacol. 2002, 437, 9-17.
244. Payen, L.; Delugin, L.; Courtois, A.; Trinquart, Y.; Guillouzo, A.; Fardel, O. Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem. Biophys. Res. Commun. 1999, 258, 513-518.
245. Sun, M.; Xu, X.; Lu, Q.; Pan, Q.; Hu, X. Schisandrin B: A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett. 2007, 246, 300-307.
246. Naito, S.; Koike, K.; Ono, M.; Machida, T.; Tasaka, S.; Kiue, A.; Koga, H.; Kumazawa, J. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance. Oncol. Res. 1998, 10, 123-132.
247. Qiangrong, P.; Wang, T.; Lu, Q.; Hu, X. Schisandrin B-a novel inhibitor of P-glycoprotein. Biochem. Biophys. Res. Commun. 2005, 335, 406-411.
248. Li, L.; Pan, Q.; Sun, M.; Lu, Q.; Hu, X. Dibenzocyclooctadiene lignans: A class of novel inhibitors of multidrug resistanceassociated protein 1. Life Sci. 2007, 80, 741-748.
249. Li, L.; Lu, Q.; Shen, Y.; Hu, X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem. Pharmacol. 2006, 71, 584-595.
250. Leslie, E.M.; Mao, Q.; Oleschuk, C.J.; Deeley, R.G.; Cole, S.P. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol. Pharmacol. 2001, 59, 1171-1180.
251. Bobrowska-Hagerstrand, M.; Lillas, M.; Mrowczynska, L.; Wrobel, A.; Shirataki, Y.; Motohashi, N.; Hagerstrand, H. Resveratrol oligomers are potent MRP1 transport inhibitors. Anticancer Res. 2006, 26, 2081-2084.
252. Weiss, J.; Theile, D.; Ketabi-Kiyanvash, N.; Lindenmaier, H.; Haefeli, W.E. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos. 2007, 35, 340-344.
253. Pan, G.; Giri, N.; Elmquist, W.F. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and Zidovudine. Drug Metab. Dispos. 2007, 35, 1165-1173.
254. Burg, D.; Wielinga, P.; Zelcer, N.; Saeki, T.; Mulder, G.J.; Borst, P. Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol. Pharmacol. 2002, 62, 1160-1166.
255. O'Brien, M.L.; Vulevic, B.; Freer, S.; Boyd, J.; Shen, H.; Tew, K.D. Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J. Pharmacol. Exp. Ther. 1999, 291, 1348-1355.
256. Payen, L.; Delugin, L.; Courtois, A.; Trinquart, Y.; Guillouzo, A.; Fardel, O. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br. J. Pharmacol. 2001, 132, 778-784.
257. Kimber-Trojnar, Z.; Marciniak, B.; Leszczynska-Gorzelak, B.; Trojnar, M.; Oleszczuk, J. Glyburide for the treatment of gestational diabetes mellitus. Pharmacol. Rep. 2008, 60, 308-318.
258. Gedeon, C.; Anger, G.; Lubetsky, A.; Miller, M.P.; Koren, G. Investigating the potential role of multi-drug resistance protein (MRP) transporters in fetal to maternal glyburide efflux in the human placenta. J. Obstet. Gynaecol. 2008, 28, 485-489.
259. Zhou, S.F.; Zhou, Z.W.; Yang, L.P.; Cai, J.P. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr. Med. Chem. 2009, 16, 3480-3675.
260. Miners, J.O.; Smith, K.J.; Robson, R.A.; McManus, M.E.; Veronese, M.E.; Birkett, D.J. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 1988, 37, 1137-1144.
261. Loo, T.W.; Clarke, D.M. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J. Natl. Cancer Inst. 2000, 92, 898-902.
262. Sauna, Z.E.; Peng, X.H.; Nandigama, K.; Tekle, S.; Ambudkar, S.V. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol. Pharmacol. 2004, 65, 675-684.
263. Zheng, L.S.; Wang, F.; Li, Y.H.; Zhang, X.; Chen, L.M.; Liang, Y.J.; Dai, C.L.; Yan, Y.Y.; Tao, L.Y.; Mi, Y.J.; Yang, A.K.; To, K.K.; Fu, L.W. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One 2009, 4, e5172.
264. Tao, L.Y.; Liang, Y.J.; Wang, F.; Chen, L.M.; Yan, Y.Y.; Dai, C.L.; Fu, L.W. Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother. Pharmacol. 2009, 64, 961-969.
265. Mi, Y.J.; Liang, Y.J.; Huang, H.B.; Zhao, H.Y.; Wu, C.P.; Wang, F.; Tao, L.Y.; Zhang, C.Z.; Dai, C.L.; Tiwari, A.K.; Ma, X.X.; To, K.K.; Ambudkar, S.V.; Chen, Z.S.; Fu, L.W. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010, 70, 7981-7991.
266. Shukla, S.; Robey, R.W.; Bates, S.E.; Ambudkar, S.V. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab. Dispos. 2009, 37, 359-365.
267. Norman, B.H.; Dantzig, A.H.; Kroin, J.S.; Law, K.L.; Tabas, L.B.; Shepard, R.L.; Palkowitz, A.D.; Hauser, K.L.; Winter, M.A.; Sluka, J.P.; Starling, J.J. Reversal of resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146. Bioorg. Med. Chem. Lett. 1999, 9, 3381-3386.
268. Norman, B.H.; Lander, P.A.; Gruber, J.M.; Kroin, J.S.; Cohen, J.D.; Jungheim, L.N.; Starling, J.J.; Law, K.L.; Self, T.D.; Tabas, L.B.; Williams, D.C.; Paul, D.C.; Dantzig, A.H. Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1). Bioorg. Med. Chem. Lett. 2005, 15, 5526-5530.
269. Norman, B.H.; Gruber, J.M.; Hollinshead, S.P.; Wilson, J.W.; Starling, J.J.; Law, K.L.; Self, T.D.; Tabas, L.B.; Williams, D.C.; Paul, D.C.; Wagner, M.M.; Dantzig, A.H. Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1). Bioorg. Med. Chem. Lett. 2002, 12, 883-886.
270. Mao, Q.; Qiu, W.; Weigl, K.E.; Lander, P.A.; Tabas, L.B.; Shepard, R.L.; Dantzig, A.H.; Deeley, R.G.; Cole, S.P. GSHdependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [125I]LY475776. Evidence of a major binding site in the COOH-proximal membrane spanning domain. J. Biol. Chem. 2002, 277, 28690-28699.
271. Qian, Y.M.; Grant, C.E.; Westlake, C.J.; Zhang, D.W.; Lander, P.A.; Shepard, R.L.; Dantzig, A.H.; Cole, S.P.; Deeley, R.G. Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]glutathione. J. Biol. Chem. 2002, 277, 35225-35231.
272. Stewart, A.J.; Canitrot, Y.; Baracchini, E.; Dean, N.M.; Deeley, R.G.; Cole, S.P. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem. Pharmacol. 1996, 51, 461-469.
273. Peaston, A.E.; Gardaneh, M.; Franco, A.V.; Hocker, J.E.; Murphy, K.M.; Farnsworth, M.L.; Catchpoole, D.R.; Haber, M.; Norris, M.D.; Lock, R.B.; Marshall, G.M. MRP1 gene expression level regulates the death and differentiation response of neuroblastoma cells. Br. J. Cancer 2001, 85, 1564-1571.
274. Niewiarowski, W.; Gendaszewska, E.; Rebowski, G.; Wojcik, M.; Mikolajczyk, B.; Goss, W.; Soszynski, M.; Bartosz, G. Multidrug resistance-associated protein-reduction of expression in human leukaemia cells by antisense phosphorothioate olignucleotides. Acta Biochim. Pol. 2000, 47, 1183-1188.
275. Kuss, B.J.; Corbo, M.; Lau, W.M.; Fennell, D.A.; Dean, N.M.; Cotter, F.E. In vitro and in vivo downregulation of MRP1 by antisense oligonucleotides: A potential role in neuroblastoma therapy. Int. J. Cancer 2002, 98, 128-133.
276. Wang, S.; Folkes, A.; Chuckowree, I.; Cockcroft, X.; Sohal, S.; Miller, W.; Milton, J.; Wren, S.P.; Vicker, N.; Depledge, P.; Scott, J.; Smith, L.; Jones, H.; Mistry, P.; Faint, R.; Thompson, D.; Cocks, S. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance. J. Med. Chem. 2004, 47, 1329-1338.
277. van Zanden, J.J.; Wortelboer, H.M.; Bijlsma, S.; Punt, A.; Usta, M.; Bladeren, P.J.; Rietjens, I.M.; Cnubben, N.H. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem. Pharmacol. 2005, 69, 699-708.
278. Wang, S.; Ryder, H.; Pretswell, I.; Depledge, P.; Milton, J.; Hancox, T.C.; Dale, I.; Dangerfield, W.; Charlton, P.; Faint, R.; Dodd, R.; Hassan, S. Studies on quinazolinones as dual inhibitors of P-gp and MRP1 in multidrug resistance. Bioorg. Med. Chem. Lett. 2002, 12, 571-574.
279. 4 or estradiol-17 (β- D-glucuronate). Biochem. Pharmacol. 2005, 70, 1056-1065.
280. Pajeva, I.K.; Globisch, C.; Wiese, M. Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors. Chem. Med. Chem. 2009, 4, 1883-1896.
281. Lather, V.; Madan, A.K. Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine. Bioorg. Med. Chem. Lett. 2005, 15, 4967-4972.
282. Wong, I.L.; Chan, K.F.; Tsang, K.H.; Lam, C.Y.; Zhao, Y.; Chan, T.H.; Chow, L.M. Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. J. Med. Chem. 2009, 52, 5311-5322.
283. Hacker, H.G.; Leyers, S.; Wiendlocha, J.; Gutschow, M.; Wiese, M. Aromatic 2-(thio)ureidocarboxylic acids as a new family of modulators of multidrug resistance-associated protein 1: Synthesis, biological evaluation, and structure-activity relationships. J. Med. Chem. 2009, 52, 4586-4595.
284. Fernandes, J.; Gattass, C.R. Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1). J. Med. Chem. 2009, 52, 1214-1218.
285. Seelig, A. A general pattern for substrate recognition by Pglycoprotein.
286. Seelig, A.; Blatter, X.L.; Wohnsland, F. Substrate recognition by Pglycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int. J. Clin. Pharmacol. Ther. 2000, 38, 111-121.
287. Raggers, R.J.; van Helvoort, A.; Evers, R.; van Meer, G. The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J. Cell Sci. 1999, 112 (Pt 3), 415-422.
288. Wang, S.; Wan, N.C.; Harrison, J.; Miller, W.; Chuckowree, I.; Sohal, S.; Hancox, T.C.; Baker, S.; Folkes, A.; Wilson, F.; Thompson, D.; Cocks, S.; Farmer, H.; Boyce, A.; Freathy, C.; Broadbridge, J.; Scott, J.; Depledge, P.; Faint, R.; Mistry, P.; Charlton, P. Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance. J. Med. Chem. 2004, 47, 1339-1350.
289. Bobrowska-Hagerstrand, M.; Wrobel, A.; Mrowczynska, L.; Soderstrom, T.; Shirataki, Y.; Motohashi, N.; Molnar, J.; Michalak, K.; Hagerstrand, H. Flavonoids as inhibitors of MRP1-like efflux activity in human erythrocytes. A structure-activity relationship study. Oncol. Res. 2003, 13, 463-469.
290. Hattori, M.; Okuno, Y.; Goto, S.; Kanehisa, M. Development of a chemical structure comparison method for integrated analysis of chemical and genomic information in the metabolic pathways. J. Am. Chem. Soc. 2003, 125, 11853-11865.
291. Tawari, N.R.; Bag, S.; Degani, M.S. Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators. J. Mol. Model. 2008, 14, 911-921.
292. Chang, C.; Ekins, S.; Bahadduri, P.; Swaan, P.W. Pharmacophorebased discovery of ligands for drug transporters. Adv. Drug Deliv. Rev. 2006, 58, 1431-1450.
293. Fruttero, R.; Crosetti, M.; Chegaev, K.; Guglielmo, S.; Gasco, A.; Berardi, F.; Niso, M.; Perrone, R.; Panaro, M.A.; Colabufo, N.A. Phenylsulfonylfuroxans as modulators of multidrug-resistanceassociated protein-1 and P-glycoprotein. J. Med. Chem. 2010, 53, 5467-5475.
294. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for polyspecific drug binding. Science 2009, 323, 1718-1722.
295. Ward, A.; Reyes, C.L.; Yu, J.; Roth, C.B.; Chang, G. Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 19005-19010.
296. Dawson, R.J.; Locher, K.P. Structure of a bacterial multidrug ABC transporter. Nature 2006, 443, 180-185.
297. Locher, K.P.; Lee, A.T.; Rees, D.C. The E. coli BtuCD structure: A framework for ABC transporter architecture and mechanism. Science 2002, 296, 1091-1098.
298. Hollenstein, K.; Frei, D.C.; Locher, K.P. Structure of an ABC transporter in complex with its binding protein. Nature 2007, 446, 213-216.
299. Pinkett, H.W.; Lee, A.T.; Lum, P.; Locher, K.P.; Rees, D.C. An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science 2007, 315, 373-377.
300. Campbell, J.D.; Koike, K.; Moreau, C.; Sansom, M.S.; Deeley, R.G.; Cole, S.P. Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1). J. Biol. Chem. 2004, 279, 463-468.
301. DeGorter, M.K.; Conseil, G.; Deeley, R.G.; Campbell, R.L.; Cole, S.P. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochem. Biophys. Res. Commun. 2008, 365, 29-34.
302. Bakos, E.; Evers, R.; Szakacs, G.; Tusnady, G.E.; Welker, E.; Szabo, K.; de Haas, M.; van Deemter, L.; Borst, P.; Varadi, A.; Sarkadi, B. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J. Biol. Chem. 1998, 273, 32167-32175.
303. Rosenberg, M.F.; Oleschuk, C.J.; Wu, P.; Mao, Q.; Deeley, R.G.; Cole, S.P.; Ford, R.C. Structure of a human multidrug transporter in an inward-facing conformation. J. Struct. Biol. 2010, 170, 540-547.
304. 4. J. Biol. Chem. 1998, 273, 10733-10740.
305. Ito, K.; Weigl, K.E.; Deeley, R.G.; Cole, S.P. Mutation of proline residues in the NH2-terminal region of the multidrug resistance protein, MRP1 (ABCC1): Effects on protein expression, membrane localization, and transport function. Biochim. Biophys. Acta 2003, 1615, 103-114.
306. Yang, Y.; Liu, Y.; Dong, Z.; Xu, J.; Peng, H.; Liu, Z.; Zhang, J.T. Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1. J. Biol. Chem. 2007, 282, 8821-8830.
307. Chen, Q.; Yang, Y.; Liu, Y.; Han, B.; Zhang, J.T. Cytoplasmic retraction of the amino terminus of human multidrug resistance protein 1. Biochemistry 2002, 41, 9052-9062.
308. Chen, Q.; Yang, Y.; Li, L.; Zhang, J.T. The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. J. Biol. Chem. 2006, 281, 31152-31163.
309. Kast, C.; Gros, P. Topology mapping of the amino-terminal half of multidrug resistance-associated protein by epitope insertion and immunofluorescence. J. Biol. Chem. 1997, 272, 26479-26487.
310. Kast, C.; Gros, P. Epitope insertion favors a six transmembrane domain model for the carboxy-terminal portion of the multidrug resistance-associated protein. Biochemistry 1998, 37, 2305-2313.
311. 4 transport by Coexpression of both half-molecules of human multidrug resistance protein in insect cells. J. Biol. Chem. 1996, 271, 27782-27787.
312. Nelson, D.A.; Bryan, J.; Wechsler, S.; Clement, J.P.t.; Aguilar- Bryan, L. The high-affinity sulfonylurea receptor: Distribution, glycosylation, purification, and immunoprecipitation of two forms from endocrine and neuroendocrine cell lines. Biochemistry 1996, 35, 14793-14799.
313. Raab-Graham, K.F.; Cirilo, L.J.; Boettcher, A.A.; Radeke, C.M.; Vandenberg, C.A. Membrane topology of the amino-terminal region of the sulfonylurea receptor. J. Biol. Chem. 1999, 274, 29122-29129.
314. Suzuki, T.; Sasaki, H.; Kuh, H.J.; Agui, M.; Tatsumi, Y.; Tanabe, S.; Terada, M.; Saijo, N.; Nishio, K. Detailed structural analysis on both human MRP5 and mouse MRP5 transcripts. Gene 2000, 242, 167-173.
315. Hopper, E.; Belinsky, M.G.; Zeng, H.; Tosolini, A.; Testa, J.R.; Kruh, G.D. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. 2001, 162, 181-191.
316. Muller, M.; Yong, M.; Peng, X.H.; Petre, B.; Arora, S.; Ambudkar, S.V. Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry 2002, 41, 10123-10132.
317. Mao, Q.; Leslie, E.M.; Deeley, R.G.; Cole, S.P. ATPase activity of purified and reconstituted multidrug resistance protein MRP1 from drug-selected H69AR cells. Biochim. Biophys. Acta 1999, 1461, 69-82.
318. Mao, Q.; Deeley, R.G.; Cole, S.P. Functional reconstitution of substrate transport by purified multidrug resistance protein MRP1 (ABCC1) in phospholipid vesicles. J. Biol. Chem. 2000, 275, 34166-34172.
319. Ramaen, O.; Masscheleyn, S.; Duffieux, F.; Pamlard, O.; Oberkampf, M.; Lallemand, J.Y.; Stoven, V.; Jacquet, E. Biochemical characterization and NMR studies of the nucleotidebinding domain 1 of multidrug-resistance-associated protein 1: Evidence for interaction between ATP and Trp653. Biochem. J. 2003, 376, 749-756.
320. Ramaen, O.; Sizun, C.; Pamlard, O.; Jacquet, E.; Lallemand, J.Y. Attempts to characterize the NBD heterodimer of MRP1: Transient complex formation involves Gly771 of the ABC signature sequence but does not enhance the intrinsic ATPase activity. Biochem. J. 2005, 391, 481-490.
321. Ramaen, O.; Leulliot, N.; Sizun, C.; Ulryck, N.; Pamlard, O.; Lallemand, J.Y.; Tilbeurgh, H.; Jacquet, E. Structure of the human multidrug resistance protein 1 nucleotide binding domain 1 bound to Mg2+/ATP reveals a non-productive catalytic site. J. Mol. Biol. 2006, 359, 940-949.
322. Payen, L.F.; Gao, M.; Westlake, C.J.; Cole, S.P.; Deeley, R.G. Role of carboxylate residues adjacent to the conserved core Walker B motifs in the catalytic cycle of multidrug resistance protein 1 (ABCC1). J. Biol. Chem. 2003, 278, 38537-38547.
323. Loo, T.W.; Clarke, D.M. Covalent modification of human Pglycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. J. Biol. Chem. 1995, 270, 22957-22961.
324. Nagata, K.; Nishitani, M.; Matsuo, M.; Kioka, N.; Amachi, T.; Ueda, K. Nonequivalent nucleotide trapping in the two nucleotide binding folds of the human multidrug resistance protein MRP1. J. Biol. Chem. 2000, 275, 17626-17630.
325. Gao, M.; Cui, H.R.; Loe, D.W.; Grant, C.E.; Almquist, K.C.; Cole, S.P.; Deeley, R.G. Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J. Biol. Chem. 2000, 275, 13098-13108.
326. Hou, Y.; Cui, L.; Riordan, J.R.; Chang, X. Allosteric interactions between the two non-equivalent nucleotide binding domains of multidrug resistance protein MRP1. J. Biol. Chem. 2000, 275, 20280-20287.
327. Chang, X.B.; Hou, Y.X.; Riordan, J.R. ATPase activity of purified multidrug resistance-associated protein. J. Biol. Chem. 1997, 272, 30962-30968.
328. Cai, J.; Daoud, R.; Georges, E.; Gros, P. Functional expression of multidrug resistance protein 1 in Pichia pastoris. Biochemistry 2001, 40, 8307-8316.
329. Lee, S.H.; Altenberg, G.A. Expression of functional multidrugresistance protein 1 in Saccharomyces cerevisiae: Effects of N- and C-terminal affinity tags. Biochem. Biophys. Res. Commun. 2003, 306, 644-649.
330. Rosenberg, M.F.; Mao, Q.; Holzenburg, A.; Ford, R.C.; Deeley, R.G.; Cole, S.P. The structure of the multidrug resistance protein 1 (MRP1/ABCC1). crystallization and single-particle analysis. J. Biol. Chem. 2001, 276, 16076-16082.
331. Rosenberg, M.F.; Callaghan, R.; Ford, R.C.; Higgins, C.F. Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J. Biol. Chem. 1997, 272, 10685-10694.
332. Manciu, L.; Chang, X.B.; Riordan, J.R.; Ruysschaert, J.M. Multidrug resistance protein MRP1 reconstituted into lipid vesicles: Secondary structure and nucleotide-induced tertiary structure changes. Biochemistry 2000, 39, 13026-13033.
333. Manciu, L.; Chang, X.; Riordan, J.R.; Buyse, F.; Ruysschaert, J.M. Nucleotide-induced conformational changes in the human multidrug resistance protein MRP1 are related to the capacity of chemotherapeutic drugs to accumulate or not in resistant cells. FEBS Lett. 2001, 493, 31-35.
334. Manciu, L.; Chang, X.B.; Buyse, F.; Hou, Y.X.; Gustot, A.; Riordan, J.R.; Ruysschaert, J.M. Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione. J. Biol. Chem. 2003, 278, 3347-3356.
335. Soszynski, M.; Kaluzna, A.; Rychlik, B.; Sokal, A.; Bartosz, G. Radiation inactivation suggests that human multidrug resistanceassociated protein 1 occurs as a dimer in the human erythrocyte membrane. Arch. Biochem. Biophys. 1998, 354, 311-316.
336. Ecker, G.F.; Pleban, K.; Kopp, S.; Csaszar, E.; Poelarends, G.J.; Putman, M.; Kaiser, D.; Konings, W.N.; Chiba, P. A threedimensional model for the substrate binding domain of the multidrug ATP binding cassette transporter LmrA. Mol. Pharmacol. 2004, 66, 1169-1179.
337. 4 binding sites. Mol. Pharmacol. 2005, 68, 1455-1465.
338. Ren, X.Q.; Furukawa, T.; Aoki, S.; Nakajima, T.; Sumizawa, T.; Haraguchi, M.; Chen, Z.S.; Kobayashi, M.; Akiyama, S. Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. J. Biol. Chem. 2001, 276, 23197-23206.
339. Haimeur, A.; Conseil, G.; Deeley, R.G.; Cole, S.P. Mutations of charged amino acids in or near the transmembrane helices of the second membrane spanning domain differentially affect the substrate specificity and transport activity of the multidrug resistance protein MRP1 (ABCC1). Mol. Pharmacol. 2004, 65, 1375-1385.
340. Haimeur, A.; Deeley, R.G.; Cole, S.P. Charged amino acids in the sixth transmembrane helix of multidrug resistance protein 1 (MRP1/ABCC1) are critical determinants of transport activity. J. Biol. Chem. 2002, 277, 41326-41333.
341. Maeno, K.; Nakajima, A.; Conseil, G.; Rothnie, A.; Deeley, R.G.; Cole, S.P. Molecular basis for reduced estrone sulfate transport and altered modulator sensitivity of transmembrane helix (TM) 6 and TM17 mutants of multidrug resistance protein 1 (ABCC1). Drug Metab. Dispos. 2009, 37, 1411-1420.
342. 4. Biochemistry 2002, 41, 14132-14140.
343. Zhang, D.W.; Nunoya, K.; Vasa, M.; Gu, H.M.; Cole, S.P.; Deeley, R.G. Mutational analysis of polar amino acid residues within predicted transmembrane helices 10 and 16 of multidrug resistance protein 1 (ABCC1): Effect on substrate specificity. Drug Metab. Dispos. 2006, 34, 539-546.
344. Koike, K.; Oleschuk, C.J.; Haimeur, A.; Olsen, S.L.; Deeley, R.G.; Cole, S.P. Multiple membrane-associated tryptophan residues contribute to the transport activity and substrate specificity of the human multidrug resistance protein, MRP1. J. Biol. Chem. 2002, 277, 49495-49503.
345. Koike, K.; Conseil, G.; Leslie, E.M.; Deeley, R.G.; Cole, S.P. Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions. J. Biol. Chem. 2004, 279, 12325-12336.
346. 4 binding sites in multidrug resistance protein 1 (ABCC1) include the first membrane multiple spanning domain. Biochemistry 2005, 44, 340-351.
347. Letourneau, I.J.; Nakajima, A.; Deeley, R.G.; Cole, S.P. Role of proline 1150 in functional interactions between the membrane spanning domains and nucleotide binding domains of the MRP1 (ABCC1) transporter. Biochem. Pharmacol. 2008, 75, 1659-1669.
348. Letourneau, I.J.; Slot, A.J.; Deeley, R.G.; Cole, S.P. Mutational analysis of a highly conserved proline residue in MRP1, MRP2, and MRP3 reveals a partially conserved function. Drug Metab. Dispos. 2007, 35, 1372-1379.
349. Yang, R.; Chang, X.B. Hydrogen-bond formation of the residue in H-loop of the nucleotide binding domain 2 with the ATP in this site and/or other residues of multidrug resistance protein MRP1 plays a crucial role during ATP-dependent solute transport. Biochim. Biophys. Acta 2007, 1768, 324-335.
350. Buyse, F.; Hou, Y.X.; Vigano, C.; Zhao, Q.; Ruysschaert, J.M.; Chang, X.B. Replacement of the positively charged Walker A lysine residue with a hydrophobic leucine residue and conformational alterations caused by this mutation in MRP1 impair ATP binding and hydrolysis. Biochem. J. 2006, 397, 121-130.
351. Zhao, Q.; Chang, X.B. Mutation of the aromatic amino acid interacting with adenine moiety of ATP to a polar residue alters the properties of multidrug resistance protein 1. J. Biol. Chem. 2004, 279, 48505-48512.
352. Szentpetery, Z.; Kern, A.; Liliom, K.; Sarkadi, B.; Varadi, A.; Bakos, E. The role of the conserved glycines of ATP-binding cassette signature motifs of MRP1 in the communication between the substrate-binding site and the catalytic centers. J. Biol. Chem. 2004, 279, 41670-41678.
353. Yang, R.; Scavetta, R.; Chang, X.B. The hydroxyl group of S685 in Walker A motif and the carboxyl group of D792 in Walker B motif of NBD1 play a crucial role for multidrug resistance protein folding and function. Biochim. Biophys. Acta 2008, 1778, 454-465.
354. Conseil, G.; Deeley, R.G.; Cole, S.P. Functional importance of three basic residues clustered at the cytosolic interface of transmembrane helix 15 in the multidrug and organic anion transporter MRP1 (ABCC1). J. Biol. Chem. 2006, 281, 43-50.
355. Conseil, G.; Rothnie, A.J.; Deeley, R.G.; Cole, S.P. Multiple roles of charged amino acids in cytoplasmic loop 7 for expression and function of the multidrug and organic anion transporter MRP1 (ABCC1). Mol. Pharmacol. 2009, 75, 397-406.
356. Westlake, C.J.; Payen, L.; Gao, M.; Cole, S.P.; Deeley, R.G. Identification and characterization of functionally important elements in the multidrug resistance protein 1 COOH-terminal region. J. Biol. Chem. 2004, 279, 53571-53583.
357. Situ, D.; Haimeur, A.; Conseil, G.; Sparks, K.E.; Zhang, D.; Deeley, R.G.; Cole, S.P. Mutational analysis of ionizable residues proximal to the cytoplasmic interface of membrane spanning domain 3 of the multidrug resistance protein, MRP1 (ABCC1): Glutamate 1204 is important for both the expression and catalytic activity of the transporter. J. Biol. Chem. 2004, 279, 38871-38880.
358. Zhang, D.W.; Cole, S.P.; Deeley, R.G. Determinants of the substrate specificity of multidrug resistance protein 1: Role of amino acid residues with hydrogen bonding potential in predicted transmembrane helix 17. J. Biol. Chem. 2002, 277, 20934-20941.
359. Zhang, D.W.; Gu, H.M.; Vasa, M.; Muredda, M.; Cole, S.P.; Deeley, R.G. Characterization of the role of polar amino acid residues within predicted transmembrane helix 17 in determining the substrate specificity of multidrug resistance protein 3. Biochemistry 2003, 42, 9989-10000.
360. Zhang, D.W.; Nunoya, K.; Vasa, M.; Gu, H.M.; Theis, A.; Cole, S.P.; Deeley, R.G. Transmembrane helix 11 of multidrug resistance protein 1 (MRP1/ABCC1): Identification of polar amino acids important for substrate specificity and binding of ATP at nucleotide binding domain 1. Biochemistry 2004, 43, 9413-9425.
361. Cui, L.; Hou, Y.X.; Riordan, J.R.; Chang, X.B. Mutations of the Walker B motif in the first nucleotide binding domain of multidrug resistance protein MRP1 prevent conformational maturation. Arch. Biochem. Biophys. 2001, 392, 153-161.
362. Conrad, S.; Kauffmann, H.M.; Ito, K.; Deeley, R.G.; Cole, S.P.; Schrenk, D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 2001, 46, 656-663.
363. Conrad, S.; Kauffmann, H.M.; Ito, K.; Leslie, E.M.; Deeley, R.G.; Schrenk, D.; Cole, S.P. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 2002, 12, 321-330.
364. Ren, X.Q.; Furukawa, T.; Haraguchi, M.; Sumizawa, T.; Aoki, S.; Kobayashi, M.; Akiyama, S. Function of the ABC signature sequences in the human multidrug resistance protein 1. Mol. Pharmacol. 2004, 65, 1536-1542.
365. Ren, X.Q.; Furukawa, T.; Yamamoto, M.; Aoki, S.; Kobayashi, M.; Nakagawa, M.; Akiyama, S. A functional role of intracellular loops of human multidrug resistance protein 1. J. Biochem (Tokyo). 2006, 140, 313-318.
366. Yin, J.Y.; Huang, Q.; Yang, Y.; Zhang, J.T.; Zhong, M.Z.; Zhou, H.H.; Liu, Z.Q. Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet. Genomics 2009, 19, 206-216.
367. Letourneau, I.J.; Deeley, R.G.; Cole, S.P. Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet. Genomics 2005, 15, 647-657.
368. Conseil, G.; Deeley, R.G.; Cole, S.P. Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas. Biochem. Pharmacol. 2005, 69, 451-461.
369. Hirokawa, T.; Boon-Chieng, S.; Mitaku, S. SOSUI: Classification and secondary structure prediction system for membrane proteins. Bioinformatics 1998, 14, 378-379.
370. Sansom, M.S.; Weinstein, H. Hinges, swivels and switches: The role of prolines in signalling via transmembrane β-helices. Trends Pharmacol. Sci. 2000, 21, 445-451.
371. Leslie, E.M.; Ito, K.; Upadhyaya, P.; Hecht, S.S.; Deeley, R.G.; Cole, S.P. Transport of the β-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J. Biol. Chem. 2001, 276, 27846-27854.
372. Kwan, T.; Loughrey, H.; Brault, M.; Gruenheid, S.; Urbatsch, I.L.; Senior, A.E.; Gros, P. Functional analysis of a tryptophan-less Pglycoprotein: A tool for tryptophan insertion and fluorescence spectroscopy. Mol. Pharmacol. 2000, 58, 37-47.
373. Zelcer, N.; Saeki, T.; Reid, G.; Beijnen, J.H.; Borst, P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J. Biol. Chem. 2001, 276, 46400-46407.
374. Grant, C.E.; Gao, M.; DeGorter, M.K.; Cole, S.P.; Deeley, R.G. Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab. Dispos. 2008, 36, 2571-2581.
375. Cremonesi, L.; Cainarca, S.; Rossi, A.; Padoan, R.; Ferrari, M. Detection of a de novo R1066H mutation in an Italian patient affected by cystic fibrosis. Hum. Genet. 1996, 98, 119-121.
376. Ringpfeil, F.; Lebwohl, M.G.; Christiano, A.M.; Uitto, J. Pseudoxanthoma elasticum: Mutations in the MRP6 gene encoding a transmembrane ATP-binding cassette (ABC) transporter. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 6001-6006.
377. Wang, Z.; Sew, P.H.; Ambrose, H.; Ryan, S.; Chong, S.S.; Lee, E.J.; Lee, C.G. Nucleotide sequence analyses of the MRP1 gene in four populations suggest negative selection on its coding region. BMC Genomics 2006, 7, 111.
378. Fukushima-Uesaka, H.; Saito, Y.; Tohkin, M.; Maekawa, K.; Hasegawa, R.; Kawamoto, M.; Kamatani, N.; Suzuki, K.; Yanagawa, T.; Kajio, H.; Kuzuya, N.; Yasuda, K.; Sawada, J. Genetic variations and haplotype structures of the ABC transporter gene ABCC1 in a Japanese population. Drug Metab. Pharmacokinet. 2007, 22, 48-60.
379. Wang, H.; Hao, B.; Zhou, K.; Chen, X.; Wu, S.; Zhou, G.; Zhu, Y.; He, F. Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: Implications for pharmacogenomic association studies. Ann. Hum. Genet. 2004, 68, 563-573.
380. Wang, Z.; Wang, B.; Tang, K.; Lee, E.J.; Chong, S.S.; Lee, C.G. A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum. Mol. Genet. 2005, 14, 2075-2087.
381. Moriya, Y.; Nakamura, T.; Horinouchi, M.; Sakaeda, T.; Tamura, T.; Aoyama, N.; Shirakawa, T.; Gotoh, A.; Fujimoto, S.; Matsuo, M.; Kasuga, M.; Okumura, K. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 2002, 25, 1356-1359.
382. Ito, S.; Ieiri, I.; Tanabe, M.; Suzuki, A.; Higuchi, S.; Otsubo, K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001, 11, 175-184.
383. Perdu, J.; Germain, D.P. Identification of novel polymorphisms in the pM5 and MRP1 (ABCC1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum. Hum. Mutat. 2001, 17, 74-75.
384. Oselin, K.; Mrozikiewicz, P.M.; Gaikovitch, E.; Pahkla, R.; Roots, I. Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: Detection of a novel mutation G816A in the human MRP1 gene. Eur. J. Clin. Pharmacol. 2003, 59, 347-350.
385. Wang, L.L.; Liu, Y.H.; Meng, L.L.; Li, C.G.; Zhou, S.F. Phenotype prediction of non-synonymous single-nucleotide polymorphisms in human ATP-binding cassette transporter genes. Basic Clin. Pharmacol. Toxicol. 2011, (in press).
386. Higgins, C.F.; Linton, K.J. The ATP switch model for ABC transporters. Nat. Struct. Mol. Biol. 2004, 11, 918-926.
387. Haimeur, A.; Conseil, G.; Deeley, R.G.; Cole, S.P. The MRPrelated and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr. Drug Metab. 2004, 5, 21-53.
388. Versantvoort, C.H.; Broxterman, H.J.; Bagrij, T.; Scheper, R.J.; Twentyman, P.R. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br. J. Cancer 1995, 72, 82-89.
389. Rothnie, A.; Callaghan, R.; Deeley, R.G.; Cole, S.P. Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). J. Biol. Chem. 2006, 281, 13906-13914.
390. Rothnie, A.; Conseil, G.; Lau, A.Y.; Deeley, R.G.; Cole, S.P. Mechanistic differences between GSH transport by multidrug resistance protein 1 (MRP1/ABCC1) and GSH modulation of MRP1-mediated transport. Mol. Pharmacol. 2008, 74, 1630-1640.
391. Renes, J.; de Vries, E.G.; Nienhuis, E.F.; Jansen, P.L.; Muller, M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 1999, 126, 681-688.
392. Chu, X.Y.; Huskey, S.E.; Braun, M.P.; Sarkadi, B.; Evans, D.C.; Evers, R. Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J. Pharmacol. Exp. Ther. 2004, 309, 156-164.
393. Peklak-Scott, C.; Townsend, A.J.; Morrow, C.S. Dynamics of glutathione conjugation and conjugate efflux in detoxification of the carcinogen, 4-nitroquinoline 1-oxide: Contributions of glutathione, glutathione S-transferase, and MRP1. Biochemistry 2005, 44, 4426-4433.
394. Zelcer, N.; Huisman, M.T.; Reid, G.; Wielinga, P.; Breedveld, P.; Kuil, A.; Knipscheer, P.; Schellens, J.H.; Schinkel, A.H.; Borst, P. Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J. Biol. Chem. 2003, 278, 23538-23544.
395. Njalsson, R.; Norgren, S. Physiological and pathological aspects of GSH metabolism. Acta Paediatr. 2005, 94, 132-137.
396. Fernandes, A.P.; Holmgren, A. Glutaredoxins: Glutathionedependent redox enzymes with functions far beyond a simple thioredoxin backup system. Antioxid. Redox Signal. 2004, 6, 63-74.
397. Rouhier, N.; Couturier, J.; Johnson, M.K.; Jacquot, J.P. Glutaredoxins: Roles in iron homeostasis. Trends Biochem. Sci. 2010, 35, 43-52.
398. Gallogly, M.M.; Starke, D.W.; Mieyal, J.J. Mechanistic and kinetic details of catalysis of thiol-disulfide exchange by glutaredoxins and potential mechanisms of regulation. Antioxid. Redox Signal. 2009, 11, 1059-1081.
399. Lillig, C.H.; Berndt, C.; Holmgren, A. Glutaredoxin systems. Biochim. Biophys. Acta 2008, 1780, 1304-1317.
400. Mustacich, D.; Powis, G. Thioredoxin reductase. Biochem. J. 2000, 346 Pt 1, 1-8.
401. Rappa, G.; Lorico, A.; Flavell, R.A.; Sartorelli, A.C. Evidence that the multidrug resistance protein (MRP) functions as a cotransporter of glutathione and natural product toxins. Cancer Res. 1997, 57, 5232-5237.
402. Paulusma, C.C.; van Geer, M.A.; Evers, R.; Heijn, M.; Ottenhoff, R.; Borst, P.; Oude Elferink, R.P. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates lowaffinity transport of reduced glutathione. Biochem. J. 1999, 338, 393-401.
403. Hirrlinger, J.; Dringen, R. Multidrug resistance protein 1-mediated export of glutathione and glutathione disulfide from brain astrocytes. Methods Enzymol. 2005, 400, 395-409.
404. Hirrlinger, J.; Konig, J.; Keppler, D.; Lindenau, J.; Schulz, J.B.; Dringen, R. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J. Neurochem. 2001, 76, 627-636.
405. Borst, P.; Zelcer, N.; van de Wetering, K.; Poolman, B. On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett. 2006, 580, 1085-1093.
406. Ballatori, N.; Hammond, C.L.; Cunningham, J.B.; Krance, S.M.; Marchan, R. Molecular mechanisms of reduced glutathione transport: Role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicol. Appl. Pharmacol. 2005, 204, 238-255.
407. 4 as a substrate for oatp1, the hepatic sinusoidal organic solute transporter. J. Biol. Chem. 1998, 273, 16184-16191.
408. Briz, O.; Romero, M.R.; Martinez-Becerra, P.; Macias, R.I.; Perez, M.J.; Jimenez, F.; San Martin, F.G.; Marin, J.J. OATP8/1B3- mediated cotransport of bile acids and glutathione: An export pathway for organic anions from hepatocytes? J. Biol. Chem. 2006, 281, 30326-30335.
409. Franco, R.; Cidlowski, J.A. SLCO/OATP-like transport of glutathione in FasL-induced apoptosis: Glutathione efflux is coupled to an organic anion exchange and is necessary for the progression of the execution phase of apoptosis. J. Biol. Chem. 2006, 281, 29542-29557.
410. He, Y.Y.; Huang, J.L.; Ramirez, D.C.; Chignell, C.F. Role of reduced glutathione efflux in apoptosis of immortalized human keratinocytes induced by UVA. J. Biol. Chem. 2003, 278, 8058-8064.
411. van den Dobbelsteen, D.J.; Nobel, C.S.; Schlegel, J.; Cotgreave, I.A.; Orrenius, S.; Slater, A.F. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J. Biol. Chem. 1996, 271, 15420-15427.
412. Hammond, C.L.; Madejczyk, M.S.; Ballatori, N. Activation of plasma membrane reduced glutathione transport in death receptor apoptosis of HepG2 cells. Toxicol. Appl. Pharmacol. 2004, 195, 12-22.
413. Ghibelli, L.; Fanelli, C.; Rotilio, G.; Lafavia, E.; Coppola, S.; Colussi, C.; Civitareale, P.; Ciriolo, M.R. Rescue of cells from apoptosis by inhibition of active GSH extrusion. FASEB J. 1998, 12, 479-486.
414. Kohno, T.; Yamada, Y.; Hata, T.; Mori, H.; Yamamura, M.; Tomonaga, M.; Urata, Y.; Goto, S.; Kondo, T. Relation of oxidative stress and glutathione synthesis to CD95(Fas/APO-1)- mediated apoptosis of adult T cell leukemia cells. J. Immunol. 1996, 156, 4722-4728.
415. Hammond, C.L.; Marchan, R.; Krance, S.M.; Ballatori, N. Glutathione export during apoptosis requires functional multidrug resistance-associated proteins. J. Biol. Chem. 2007, 282, 14337-14347.
416. Leslie, E.M.; Deeley, R.G.; Cole, S.P. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab. Dispos. 2003, 31, 11-15.
417. Galati, G.; Chan, T.; Wu, B.; O'Brien, P.J. Glutathione-dependent generation of reactive oxygen species by the peroxidase-catalyzed redox cycling of flavonoids. Chem. Res. Toxicol. 1999, 12, 521-525.
418. Feller, N.; Broxterman, H.J.; Wahrer, D.C.; Pinedo, H.M. ATPdependent efflux of calcein by the multidrug resistance protein (MRP): No inhibition by intracellular glutathione depletion. FEBS Lett. 1995, 368, 385-388.
419. Chen, Z.S.; Furukawa, T.; Sumizawa, T.; Ono, K.; Ueda, K.; Seto, K.; Akiyama, S.I. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK- 104P. Mol. Pharmacol. 1999, 55, 921-928.
420. Vezmar, M.; Deady, L.W.; Tilley, L.; Georges, E. The quinolinebased drug, N- [4- [1-hydroxy-2-(dibutylamino)ethyl] quinolin-8- yl]-4-azidosalicylamide, photoaffinity labels the multidrug resistance protein (MRP) at a biologically relevant site. Biochem. Biophys. Res. Commun. 1997, 241, 104-111.
421. Schneider, E.; Yamazaki, H.; Sinha, B.K.; Cowan, K.H. Buthionine sulphoximine-mediated sensitisation of etoposide-resistant human breast cancer MCF7 cells overexpressing the multidrug resistanceassociated protein involves increased drug accumulation. Br. J. Cancer 1995, 71, 738-743.
422. 4). Biochem. J. 2003, 371, 361-367.
423. Wesolowska, O.; Mosiadz, D.; Motohashi, N.; Kawase, M.; Michalak, K. Phenothiazine maleates stimulate MRP1 transport activity in human erythrocytes. Biochim. Biophys. Acta 2005, 1720, 52-58.
424. Cullen, K.V.; Davey, R.A.; Davey, M.W. Verapamil-stimulated glutathione transport by the multidrug resistance-associated protein (MRP1) in leukaemia cells. Biochem. Pharmacol. 2001, 62, 417-424.
425. Yu, X.Q.; Xue, C.C.; Wang, G.; Zhou, S.F. Multidrug resistance associated proteins as determining factors of pharmacokinetics and pharmacodynamics of drugs. Curr. Drug Metab. 2007, 8, 787-802.
426. Cascorbi, I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 2006, 112, 457-473.
427. Zhou, S.F.; Di, Y.M.; Chan, E.; Du, Y.M.; Chow, V.D.; Xue, C.C.; Lai, X.; Wang, J.C.; Li, C.G.; Tian, M.; Duan, W. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 2008, 9, 738-784.
428. Zhou, S.F. Pharmacogenetics of human multidrug resistance associated proteins. Curr. Pharmacogenom. Pers. Med. 2008, 6, 134-149.
429. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
430. Haber, M.; Smith, J.; Bordow, S.B.; Flemming, C.; Cohn, S.L.; London, W.B.; Marshall, G.M.; Norris, M.D. Association of highlevel MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J. Clin. Oncol. 2006, 24, 1546-1553.
431. Lee, S.H.; Lee, M.S.; Lee, J.H.; Kim, S.W.; Kang, R.H.; Choi, M.J.; Park, S.J.; Kim, S.J.; Lee, J.M.; Cole, S.P.; Lee, M.G. MRP1 polymorphisms associated with citalopram response in patients with major depression. J. Clin. Psychopharmacol. 2010, 30, 116-125.
432. Warren, R.B.; Smith, R.L.; Campalani, E.; Eyre, S.; Smith, C.H.; Barker, J.N.; Worthington, J.; Griffiths, C.E. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J. Invest. Dermatol. 2008, 128, 1925-1929.
433. van der Deen, M.; Marks, H.; Willemse, B.W.; Postma, D.S.; Muller, M.; Smit, E.F.; Scheffer, G.L.; Scheper, R.J.; de Vries, E.G.; Timens, W. Diminished expression of multidrug resistanceassociated protein 1 (MRP1) in bronchial epithelium of COPD patients. Virchows Arch. 2006, 449, 682-688.
434. Siedlinski, M.; Boezen, H.M.; Boer, J.M.; Smit, H.A.; Postma, D.S. ABCC1 polymorphisms contribute to level and decline of lung function in two population-based cohorts. Pharmacogenet. Genomics 2009, 19, 675-684.
435. Allen, J.D.; Brinkhuis, R.F.; van Deemter, L.; Wijnholds, J.; Schinkel, A.H. Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res. 2000, 60, 5761-5766.
436. Smeets, M.E.; Raymakers, R.A.; Vierwinden, G.; Pennings, A.H.; Boezeman, J.; Minderman, H.; de Witte, T.M. Idarubicin DNA intercalation is reduced by MRP1 and not Pgp. Leukemia 1999, 13, 1390-1398.
437. Pham, A.N.; Wang, J.; Fang, J.; Gao, X.; Zhang, Y.; Blower, P.E.; Sadee, W.; Huang, Y. Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins. Pharm. Res. 2009, 26, 936-945.
438. Okada, T.; Tanaka, K.; Nakatani, F.; Sakimura, R.; Matsunobu, T.; Li, X.; Hanada, M.; Nakamura, T.; Oda, Y.; Tsuneyoshi, M.; Iwamoto, Y. Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int. J. Cancer 2006, 118, 90-97.
439. Xiao, J.J.; Foraker, A.B.; Swaan, P.W.; Liu, S.; Huang, Y.; Dai, Z.; Chen, J.; Sadee, W.; Byrd, J.; Marcucci, G.; Chan, K.K. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by Pglycoprotein and multidrug resistance-associated protein 1. J. Pharmacol. Exp. Ther. 2005, 313, 268-276.
440. Olson, D.P.; Scadden, D.T.; D'Aquila, R.T.; De Pasquale, M.P. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). Aids 2002, 16, 1743-1747.
441. Michot, J.M.; Van Bambeke, F.; Mingeot-Leclercq, M.P.; Tulkens, P.M. Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter. Antimicrob. Agents Chemother. 2004, 48, 2673-2682.
442. Sasabe, H.; Kato, Y.; Suzuki, T.; Itose, M.; Miyamoto, G.; Sugiyama, Y. Differential involvement of multidrug resistanceassociated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. J. Pharmacol. Exp. Ther. 2004, 310, 648-655.
443. Laochariyakul, P.; Ponglikitmongkol, M.; Mankhetkorn, S. Functional study of intracellular P-gp- and MRP1-mediated pumping of free cytosolic pirarubicin into acidic organelles in intrinsic resistant SiHa cells. Can. J. Physiol. Pharmacol. 2003, 81, 790-799.
444. Tamai, I.; Yamashita, J.; Kido, Y.; Ohnari, A.; Sai, Y.; Shima, Y.; Naruhashi, K.; Koizumi, S.; Tsuji, A. Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier. J. Pharmacol. Exp. Ther. 2000, 295, 146-152.
445. Ishikawa, T.; Bao, J.J.; Yamane, Y.; Akimaru, K.; Frindrich, K.; Wright, C.D.; Kuo, M.T. Coordinated induction of MRP/GS-X pump and gamma- glutamylcysteine synthetase by heavy metals in human leukemia cells. J. Biol. Chem. 1996, 271, 14981-14988.
446. Draper, M.P.; Martell, R.L.; Levy, S.B. Active efflux of the free acid form of the fluorescent dye 2',7'-bis(2-carboxyethyl)-5(6)- carboxyfluorescein in multidrug-resistance-protein-overexpressing murine and human leukemia cells. Eur. J. Biochem. 1997, 243, 219-224.
447. Essodaigui, M.; Broxterman, H.J.; Garnier-Suillerot, A. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 1998, 37, 2243-2250.
448. Hollo, Z.; Homolya, L.; Hegedus, T.; Sarkadi, B. Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett. 1996, 383, 99-104.
449. Tribull, T.E.; Bruner, R.H.; Bain, L.J. The multidrug resistanceassociated protein 1 transports methoxychlor and protects the seminiferous epithelium from injury. Toxicol. Lett. 2003, 142, 61-70.
450. Beedholm-Ebsen, R.; van de Wetering, K.; Hardlei, T.; Nexo, E.; Borst, P.; Moestrup, S.K. Identification of multidrug resistance protein 1 (MRP1/ABCC1) as a molecular gate for cellular export of cobalamin. Blood 2010, 115, 1632-1639.
451. Videmann, B.; Mazallon, M.; Prouillac, C.; Delaforge, M.; Lecoeur, S. ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites. Toxicol. Lett. 2009, 190, 215-223.
452. 4 export mechanism in human platelets: Possible involvement of multidrug resistance-associated protein 1. J. Lipid Res. 1999, 40, 439-446.
453. Keppler, D.; Leier, I.; Jedlitschky, G.; Konig, J. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem. Biol. Interact. 1998, 111-112, 153-161.
454. 4 express the MRP1 gene-encoded conjugate export pump. Biol. Chem. 1998, 379, 1121-1126.
455. Jedlitschky, G.; Leier, I.; Buchholz, U.; Hummel-Eisenbeiss, J.; Burchell, B.; Keppler, D. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem. J. 1997, 327 (Pt 1), 305-310.
456. Keppler, D.; Leier, I.; Jedlitschky, G. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol. Chem. 1997, 378, 787-791.
457. Hooijberg, J.H.; Jansen, G.; Assaraf, Y.G.; Kathmann, I.; Pieters, R.; Laan, A.C.; Veerman, A.J.; Kaspers, G.J.; Peters, G.J. Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1). Biochem. Pharmacol. 2004, 67, 1541-1548.
458. Watts, R.N.; Hawkins, C.; Ponka, P.; Richardson, D.R. Nitrogen monoxide (NO)-mediated iron release from cells is linked to NOinduced glutathione efflux via multidrug resistance-associated protein 1. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 7670-7675.
459. Nieuwenhuis, B.; Luth, A.; Chun, J.; Huwiler, A.; Pfeilschifter, J.; Schafer-Korting, M.; Kleuser, B. Involvement of the ABCtransporter ABCC1 and the sphingosine 1-phosphate receptor subtype S1P3 in the cytoprotection of human fibroblasts by the glucocorticoid dexamethasone. J. Mol. Med. 2009, 87, 645-657.